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Summary 
RNA interference (RNAi) is a natural mechanism by which small interfering RNA (siRNA) 
or short hairpin RNA (shRNA) can mediate inhibition of translation or degradation of a target 
RNA molecule in a sequence-specific manner. RNAi is widely used to uncover gene function 
or pathway context of novel genes. In this study, two loss-of-function screens are performed 
using RNAi for the identification of genes, which are involved in cell survival and/or 
apoptosis pathway. One screen was performed using short hairpin RNAs targeting 288 
functionally uncharacterized or poorly characterized human genes to identify those with a 
capability to inhibit apoptosis in non-tumorigenic cells. In this study, we identified a new anti-
apoptotic function for CHMP5 (Charged Multivesicular Body Protein 5), which was 
confirmed by caspase inhibition assays. Furthermore, upon over-expression of CHMP5 a 
regulatory role for CHMP5 on different signaling pathways, including NF-κB, was revealed 
by expression profiling. The regulatory effect of CHMP5 on the NF-κB-pathway was 
confirmed using luciferase reporter assays. Further investigation of upstream effectors, like 
membrane receptors, indicated that cellular surface appearance of death receptor TNFR1 is 
affected in CHMP5 modulated cells as well. Taken together, this study revealed an anti-
apoptotic function of CHMP5, and provided evidence for TNFR1 surface expression as an 
upstream and NF-κB signaling as a downstream factor with respect to CHMP5 function.  
The second screen was performed in a breast cancer cell line. SiRNAs against 107 genes over-
expressed in breast cancer patients resistant to the chemotherapy were applied to identify 
genes which have an impact on survival in breast cancer. It led to identification of PPP1R15B 
(Protein phosphatase 1 regulatory (inhibitor) subunit 15B) as a gene increasing survival of 
breast cancer cell line MCF7. Moreover, cell cycle analysis showed that PPP1R15B silencing 
inhibits cell cycle progression apparently through block of the G1/S checkpoint. Induction of 
apoptosis and inhibition of cell proliferation seem to be the mechanism through which 
deficiency of PPP1R15B affect survival of MCF7 breast cancer cells. These two studies 
provided evidence that loss-of-function screen using RNAi is a powerful approach to identify 
novel factors which are implicated in cell survival and apoptosis pathways in non- 
tumorigenic and in cancer cells. The profound influence of PPP1R15B silencing on viability 
of cancer cells, may open a possible avenue for treatment of patients resistant to 
chemotherapy in future. 
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Zusammenfassung 
Interferenz (RNAi) ist ein natürlicher Vorgang im Zellgeschehen, bei dem small interfering 
RNAs (siRNA) oder short hairpin RNAs (shRNA) die Inhibition der Translation  oder den 
Verdau von Ziel-RNAs bewirken, die sequenzhomolog erkannt werden. RNAi wird vielfältig 
eingesetzt, um die Funktion von Genen oder deren Einbindung in zelluläre Reaktionsketten zu 
untersuchen. In der vorliegende Arbeit werden zwei loss-of-function screens unter 
Verwendung von RNAi zur systematischen Suche nach Genen beschrieben, die für das 
Überleben von Zellen und/oder an der Apoptose beteiligt sind. Der erste Screen wurde mit 
shRNAs gegen 288 nicht oder kaum charakterisierten Zielgenen durchgeführt, um Kandidaten 
mit einem hemmenden Einfluss auf die Apoptose in nicht-Tumor Zellen zu bestimmen. Mit 
diesem Ansatz konnten wir eine neue anti-apoptotische Wirkung für CHMP5 (Charged 
Multivesicular Body Protein 5) nachweisen, was sich durch Caspase-Hemmung bestätigen 
ließ. Darüberhinaus zeigten Expressions-Profile nach Überexpressions von CHMP5 dessen 
regulierenden Einfluss auf unterschiedliche Signalwege, einschließlich NF-κB. Der Einfluss 
von CHMP5 auf den NF-κB-Signalweg wurde durch Luciferase-Reporter Analysen bestätigt. 
Weiterführende Untersuchungen an vorgeschalteten Effektoren, z.B. Membranrezeptoren, 
wiesen darauf hin, dass die Aktivierung des death receptors TNFR1 auf der Zelloberfläche 
ebenfalls von CHMP5 abhängig ist. Zusammenfassend zeigte die Studie eine anti-
apoptotische Funktion von CHMP5 und ergab Hinweise darauf, dass die Oberflächen-
Expression von TNFR1 ein CHMP5-vorgeschalteter, und NF-κB signaling ein CHMP5-
nachgeschalteter Faktor Vorgang sind. 
Der zweite Screen wurde mit einer Brustkrebs-Zelllinie durchgeführt. SiRNAs gegen 107 
Gene, die bekanntermaßen in chemotherapieresistenten Brustkrebspatientinnen 
überexprimiert sind, wurden eingesetzt, um Gene zu identifizieren, die für das Überleben von 
Brustkrebszellen wichtig sind. Dies führte zum Nachweis dafür, dass PPP1R15B (Protein 
phosphatase 1 regulatory (inhibitor) subunit 15B) das Überleben von MCF7 Zellen erhöht. 
Darüberhinaus zeigte eine Zellzyklus-Analyse, dass Unterdrückung von PPP1R15B den 
Ablauf des Zellzyklus' anscheinend durch Blockierung des G1/S checkpoint hemmt. 
Induktion von Apoptose und Hemmung der Zellvermehrung scheinen der Mechanismus zu 
sein, durch den ein Ausfall von PPP1R15B auf das Überleben von MCF7-Brustkrebs Zellen 
einwirkt. 
Zusammenfassung 
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Diese beiden Untersuchungen erbringen den Nachweis, dass loss-of-function screens mittels 
RNAi ein leistungsfähiger Ansatz sind, um neue Faktoren zu finden, die das Überleben von 
Zellen und deren Apoptose in nicht-neoplastischen, sowie in Tumorzellen beeinflussen. Der 
grundlegende Einfluss der Unterdrückung von PPP1R15B auf die Lebensfähigkeit von Krebs-
Zellen könnte einen Weg zur Behandlung von Chemotherapie-resistenten Patienten öffnen.
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Abbreviation 
ATP Adenosine triphosphate 
Birc Baculovirus IAP repeat (BIR)-containing 
protein 
BSA Bovine serum albumin 
bp  Base pair  
cDNA Complementary DNA 
CGPA Comprehensive Gene Pathway Analysis 
CHMP5 Charged Multivesicularbody Protein 5 
dNTP  Desoxy-nucleotide triphosphate  
ds  Double stranded  
DNA  Desoxy-ribonucleic acid  
DISC Death-inducing signaling complex 
DD Death domain 
ESCRT-III  Endosomal sorting complex required for 
transport III 
eIF2 α Eukaryotic translation initiation factor 2α 
E. coli Escherichia coli 
FACS  Fluorescence-activated cell sorting  
GEO Gene Expression Omnibus 
GFP  Green fluorescent protein  
IAP Inhibitor of apoptosis proteins 
IPA Ingenuity Pathways analysis 
RLU Related light units 
Luc                                        Luciferase 
LB  Lysogeny Broth / Luria Broth  
mRNAs Messenger RNAs 
NF-κB  Nuclear Factor kappa B  
PCD Programmed cell death 
PPP1R15B Protein Phosphatase 1 Regulatory (inhibitor) 
Subunit 15B 
Abbreviation 
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PVDF  Polyvinylidene fluoride  
PI  Propidium iodide  
PBS  Phosphate buffered saline  
qRT-PCR  Quantitative real-time polymerase chain 
reaction  
RNAi RNA interference 
RISC RNA-induced silencing complex 
RT  Room temperature  
RPM  Rotations per minute  
RNA  Ribonucleic acid  
SDS  Sodium dodecyl sulfate  
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis  
Sh  Short hairpin  
ShRNAs Short hairpin RNAs 
SiRNAs Small interfering RNAs 
TNFR1 Tumour Necrosis Factor Receptor 1 
v/v Volume per volume 
Vol Volume 
W/v Weight per volume 
YFP                                 Yellow fluorescent protein 
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I Introduction 
I-1 Apoptosis 
The physiological cell death that occurs in multicellular organisms is called „programmed cell 
death‟ (PCD) or apoptosis. Apoptosis is derived from the Greek word for "falling off" of 
leaves from a tree. The term apoptosis (ap-op-toe-sis) was first used in a, now-classic, paper 
by Kerr, Wyllie, and Currie in 1972 to describe a morphologically distinct form of cell death, 
although certain components of the apoptosis concept had been explicitly described many 
years previously (Kerr et al., 1972; Kerr, 2002; Chowdhury et al., 2006). Apoptosis is a 
crucial biological process and plays an essential role in regulating development, homeostasis, 
and immune defence. It is a biologically conserved phenomenon throughout evolution, and is 
observed from nematodes to mammals. The process of apoptosis is the end of an energy-
dependent cascade of events initiated by death-inducing stimuli (Vaux and Strasser, 1996; 
Vaux and Korsmeyer, 1999; Chowdhury et al., 2006). The process of apoptosis is divided into 
different phases containing overlapping components: 
i. In the early or initiation phase a stimulus provokes or initiates the apoptotic response. This 
may be an external signal delivered through surface receptors, or may originate inside the cell 
from the action of a drug, toxin, or radiation. 
ii. The signal transduction phase, in which the detection of a signal or metabolic state results 
in the transduction of that signal to the cell death effector machinery, resulting in the 
activation of proteases. 
iii. The termination phase, in which results the cell‟s chromatin and DNA are degraded. 
I.1.2 Morphological features and detection of apoptosis 
Morphological alterations that occur upon
 
apoptotic cell death involve both the nucleus and 
the cytoplasm. Light and electron microscopy have identified various changes, including cell 
shrinkage, surface convolution, and the formation of apoptotic bodies (Hacker, 2000). Using 
hematoxylin and eosin staining, an apoptotic cell appears as a round or oval mass with an 
intensely eosinophilic cytoplasm, and is accompanied by vacuolization and the presence of 
dense nuclear chromatin fragments. Apoptotic chromatin condensation and nuclear 
fragmentation occurs in two stages. Condensation starts peripherally along the nuclear
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membrane, forming a crescent or ring-like structure. Chromatin cleavage occurs rapidly 
thereafter by topoisomerase II and DNAse I/DNAse II mediated enzyme activity, resulting in 
the formation of oligonucleosome-sized fragments (Earnshaw, 1995; Chowdhury et al., 2006). 
A number of techniques are available for the detection of apoptosis (Barrett et al., 2001): 
i. Detection of a so-called ladder of degenerated DNA fragments, which can be identified by 
DNA agarose gel electrophoresis (Wyllie, 1980).  
ii. Flow cytometry assays for the detection of apoptosis. Flow cytometric analyses are based 
on the detection of signals changed due to DNA fragmentation, DNA loss, or membrane 
changes. The easiest and quickest method for measuring apoptosis is DNA staining with PI 
(Nicoletti et al., 1991), which is particularly suitable for large scale in vitro studies of late 
apoptosis.In addition, due to the plasma membrane changes during apoptosis, Hoechst and 
annexin V-FITC dyes can be used for early detection of apoptosis. (Hardin et al., 1992) 
(Koopman et al., 1994).  
iii. Terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick-end labeling 
(TUNEL). DNA strand breaks occurring in apoptotic cells as a result of endonuclease(s) 
activation can be labeled in situ in individual fixed, permeabilized cells or in tissue sections 
by the terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) 
technique (Sgonc et al., 1996), which transfers biotin labeled-dUTP to these strand breaks of 
cleaved DNA by terminal transferase. 
iv. Detection of activated caspases.  Active caspases (see section I.1.4.1) can be detected 
using different methods such as flow cytometry, immunostaining and luminescent assays. 
I.1.3 Apoptotic pathways 
Apoptotic pathways can potentially be modulated to maintain cell viability. In mammals, 
apoptosis is initiated by two major pathways: 
 i. The extrinsic pathway, which can be triggered by activation of transmembrane death 
receptors and subsequent caspase-8 activation;  
ii. The intrinsic or mitochondrial pathway, which is initiated by cellular stress followed by 
activation of caspase-9.  
Each of these pathways converges to a common execution phase of apoptosis that requires 
proteolytic activation of caspases-3 and/or -7 from their inactive zymogens (Thornberry and 
Lazebnik, 1998). Biochemically, the main features of apoptosis include caspase cascade 
activation and DNA fragmentation (Adams, 2003). 
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I.1.3.1 The death receptor-mediated apoptotic pathway (extrinsic pathway) 
The receptors triggering this pathway are located in the cell membrane and are activated by 
extra cellular ligands. Typical death receptors are Fas (also called Apo-1 or CD95) and tumor 
necrosis factor receptor (TNF-R) 1; they belong to the TNF-R family and contain a cytosolic 
death domain. Activation of death receptors causes formation of death-inducing signaling 
complexes (DISC) in which the adaptor proteins such as FADD bind with their death domain 
(DD) to a DD in the cytoplasmic region of the receptors (Ashkenazi and Dixit, 1998; Schulze-
Osthoff et al., 1998; Peter and Krammer, 2003). The receptor-induced pathway leads to the 
recruitment of caspase-8 or -10 (initiator caspases) to the DISC (Bodmer et al., 2000). The 
activated caspase then proteolytically activates downstream effector caspases that degrade 
cellular targets and mediates cell death. There is a cross-link between the two-apoptotic 
pathways, in which caspase-8 can also cleave the protein Bid. The resulting truncated Bid 
(tBid) then moves to the mitochondria and induces cytochrome c release, leading to activation 
of caspase-9 and caspase-3. DISC signalling can be inhibited by expression of c- FLIP, an 
inactive homolog of caspase-8 (Li and Yuan, 2008) (Figure 1). 
I.1.3.2 The mitochondria-mediated apoptotic pathway (intrinsic pathway) 
The intrinsic or mitochondrial pathway is activated by a variety
 
of extra- and intracellular 
stresses, including oxidative stress,
 
irradiation, and treatment with cytotoxic drugs, oncogene 
activation or DNA damage (Figure 1).
 
Mitochondria play a key role in mediating apoptosis 
induced by diverse stimuli (Wang, 2001). They release pro-apoptotic proteins (cytochrome c, 
Smac, Omi, Aif, and EndoG) whose release from the intermembrane space of mitochondria 
into the cytosol is regulated by proteins belonging to the Bcl2 family (see section I.1.4.3). 
Perhaps the most intriguing one of these proteins is cytochrome c, which binds to, and 
activates, the protein APAF1 in the cytoplasm. The binding of cytochrome c to APAF1 
induces a conformational change that allows APAF1 to bind to ATP/dATP in order to form 
the apoptosome, which mediates the activation of caspase-9 (Li et al., 1997; Rodriguez and 
Lazebnik, 1999; Jiang and Wang, 2000; Riedl and Shi, 2004), thereby triggering a cascade of 
caspase activation. 
 
Introduction 
 
 4 
 
Figure 1- The molecular mechanisms of apoptosis. Apoptosis pathways can be initiated 
via different stimuli, i.e. at the plasma membrane by death receptor ligation (extrinsic 
pathway) or at the mitochondria (intrinsic pathway). Stimulation of death receptors results in 
receptor aggregation and recruitment of the adaptor molecule Fas-associated death domain 
(FADD) and caspase-8. Upon recruitment, caspase-8 becomes activated and initiates 
apoptosis by direct cleavage of downstream effector caspases. Mitochondria are engaged 
via the intrinsic pathway, which can be initiated by a variety of stress stimuli, including 
ultraviolet (UV) radiation, γ-irradiation, heat, DNA damage, the actions of some oncoproteins 
and tumor suppressor genes (i.e., p53), viral virulence factors and most chemotherapeutic 
agents (Ghavami et al., 2009a). 
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I.1.4 Regulation and molecular mechanism of apoptosis 
Each step of apoptosis requires many proteins (Barrett et al., 2001) and among the most 
crucial are the caspases. Caspase activities are tightly regulated by the inhibitor of apoptosis 
proteins (IAP). Other families of cellular proteins are also involved in the regulation of 
apoptosis at different stages. These proteins are categorized as the Bcl-2/ Bax family and TNF 
family (Chowdhury et al., 2006; Ghavami et al., 2009b) . 
I.1.4.1 Caspases 
Caspases, a family of cysteine proteases, play a central role in apoptosis. They are a conserved 
family of enzymes that initiates a process resulting in cell death. At least 14 distinct 
mammalian caspases have been identified, of which 11 are present in human beings (Salvesen 
and Dixit, 1997; Shi, 2002; Riedl and Shi, 2004; Lavrik et al., 2005). Among them, caspases 1, 
4, and 5 play roles in inflammatory responses and caspase 2, 8, 9, and 10 are responsible for 
the initiation of apoptosis. All caspases are produced in cells as catalytically inactive 
zymogens (inactive enzyme precursors) and must undergo proteolytic processing and 
activation during apoptosis (Yan and Shi, 2005; Chowdhury et al., 2006). Caspases become 
active in response to specific signals generated by selective proteolytic processing at specific 
aspartic acid residues, which produce subunits that form an active protease, which initiates 
apoptosis (Lavrik et al., 2005). Activation of a caspase can be initiated by different 
mechanisms. Initiator caspases can be activated at the plasma membrane upon activation of 
death receptors, or by releasing of factors such as cytochrome c from mitochondria (see 
section I.1.3.1 and I.1.3.2). 
I.1.4.2 Caspase regulators 
In normal living cells, caspase activation and activity are carefully regulated at several levels 
by a family of cellular proteins called the inhibitor of apoptosis proteins (IAP). IAPs, also 
known as baculovirus IAP repeat (Bir)-containing proteins (Bircs), are evolutionarily 
conserved and structurally similar proteins. They share one to three copies of a conserved 
domain of about 70 amino-acids, named Bir. They have been identified in a large range of 
organisms including yeast, nematode, drosophila, fish and mammals. Eight members of this 
family have been described in humans (Birc1/Naip, Birc2/cIAP1, Birc3/cIAP2, Birc4/XIAP, 
Birc5/Survivin, Birc6/Apollon, Birc7/Ml-IAP and Birc8/ILP2) (LaCasse et al., 1998; 
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Salvesen and Duckett, 2002).  
Most of IAPs are able to bind to several apoptotic caspases. The capacity of Birc4/XIAP to 
inhibit the catalytic activity of caspases-3, -7 and -9 is well known (Shiozaki et al., 2003). A 
group of IAPs like XIAP, cIAP1 and cIAP2 can prevent the proteolytic processing of pro-
caspases -3, -6 and -7 by blocking the cytochrome c-induced activation of pro-caspase-9. In 
contrast, these IAP family proteins do not prevent caspase-8-induced proteolytic activation of 
pro-caspase-3. However, they subsequently can inhibit active caspase-3 directly, thus 
blocking downstream apoptotic events, such as further activation of other caspases (Deveraux 
et al., 1998). 
I.1.4.3 Bcl-2 family proteins 
The Bcl-2 (B-cell CLL/Lymphoma 2) family proteins are known to play a crucial role in the 
regulation of apoptosis. This family consists of both pro- and anti-apoptotic members, which 
elicit opposing effects on mitochondria. Pro-apoptotic members such as Bax can induce 
mitochondrial membrane permeability, which results in the release of factors including 
cytochrome c, AIF, Endo G, Smac/Diablo and Htra2/Omi. Anti-apoptotic members, such as 
Bcl-2, Mcl-1 and Bcl-XL, preserve mitochondrial integrity and, therefore, potentially block 
the release of soluble membrane proteins (Figure 1). 
The members of this family possess conserved Bcl-2 homology domains (BH), and can be 
divided into three categories (Borner, 2003; Chowdhury et al., 2006): 
i. The multi-domain pro-apoptotic members such as Bax, Boc and Bak possess BH1, BH2 and 
BH3 domains. 
ii. The „BH3-only‟ pro-apoptotic members such as Bid, Bik, Bad, Bcl2L11, Noxa and Puma. 
These share sequence homology only in the BH3 domain. 
iii. Anti-apoptotic members such as Bcl-2, Bcl-XL and Bcl2L2, all of which exert anti-cell 
death activity and share sequence conservation within all four BH domains. 
I.1.4.4 TNF family and receptors 
Tumour Necrosis Factor (TNF) is a soluble inflammatory cytokine produced by 
macrophages/monocytes during acute inflammation and is responsible for a diverse range of 
signaling events within cells, leading to apoptosis, cell proliferation, inflammation, allergy or 
autoimmune disease. The protein is also important for resistance to infection and cancer 
treatment. TNF exerts many of its effects by binding to the cognate membrane receptors 
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termed TNFR-1(CD120a) or a TNFR-2 (CD120b). Both of these receptors belong to the TNF 
receptor superfamily. The signal transduction of cell death from TNFR-1 is via its 
cytoplasmic death domain (DD) by the activation of caspase 8 alone to activate caspase 3 or 
by the activation of the mitochondria-dependent amplification loop to cause apoptosis. TNF-
R2 directly recruits TNF receptor-associated factors (TRAF), induces gene expression and 
intensively cross-talks with TNFR-1 (Idriss and Naismith, 2000; He and Ting, 2002; Micheau 
and Tschopp, 2003; Wajant et al., 2003). Death domains are also found in a further subgroup 
of the TNF receptor family members (Singh et al., 1998). These death receptors (DR) include 
the p55 receptor for TNF (TNF-R55), the CD95 molecule (Fas, Apo-1), DR3, DR6, and the 
two receptors for the TNF related apoptosis-inducing ligand (TRAIL), DR4 (Apo2, TRAIL-
R1) and DR5 (KILLER, TRAIL-R2), although Fas ligand and TRAIL, mainly induce 
apoptosis on cells expressing their receptors (Luschen et al., 2000). 
I.2 Cancer 
Cancer is a highly complex and heterogeneous disease. According to estimations by the 
World Health Organization (WHO), more than 100 different types of cancers and respective 
subtypes have been described. Each type is a clinically distinct disease, but they share the 
ability to grow in an uncontrolled way, resulting in the formation of an unstructured tissue 
mass called a tumor. The fact that not all developed tumors are dangerous is used to 
distinguish two classes: benign and malignant cancers. Benign cancers are those which 
proliferate, but do not invade the adjacent tissue. They are rarely life-threatening if they can 
be removed surgically. On the other hand, malignant cancers grow and penetrate adjacent 
tissues. When infiltrating into the blood stream, they can form new tumors in areas very 
distant from their place of origin. This behavior is called metastatic potential and describes the 
aggressiveness of the corresponding cancer. Worldwide, metastasizing cancers are responsible 
for 90% of cancer associated deaths. Among them, carcinomas (epithelial cancer) are the most 
common and aggressive types accounting for 80% of cancer-related deaths (Parkin et al., 
2001). 
Hanahan and Weinberg reviewed in 2000 six crucial steps in the transformation process of a 
normal to a malignant cell (Hanahan and Weinberg, 2000). The „hallmarks of cancer‟ are 
alterations in cell physiology that constitutively influence malignant cell growth (Figure 2). 
All of these physiological changes are novel capabilities acquired during tumor development. 
They represent the successful suppression of an anticancer defence mechanism tightly 
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connected to cells and tissues. The mechanistic pathways vary from cell to cell, and not all six 
hallmarks have to be fulfilled in each malignant cellular transformation. 
 
 
Figure 2- Acquired capabilities of cancer (Hanahan and Weinberg, 2000). 
I.2.1 Apoptosis and Cancer 
Cancer is a disorder that can be characterized by uncontrolled cell division and/or the cellular 
resistance to apoptosis. Apoptosis is a physiological process that occurs in all tissues and 
under a variety of circumstances. The balance between normal cell division, differentiation 
and apoptosis is tightly regulated in order to ensure the integrity of organs and tissues. The 
inactivation of programmed cell death has profound effects, not only on the development but 
also on the overall integrity of multicellular organisms. Beside developmental abnormalities, 
it may lead to tumorigenesis and other serious health problems. The idea that tumor 
development and progression could be influenced by apoptosis goes back to Kerr, Wyllie  and 
Currie‟s original 1972 paper, in which they showed that the observed growth rate of tumors 
was less than the predicted rate as a result of a high level of endogenous tumor cell apoptosis 
(Crawford et al., 1972; Kerr et al., 1972). Subsequent studies showed that apoptosis played an 
integral part in tumor growth, progression and resistance to therapy (Kerr et al., 1994). The 
average adult human body generated approximately 6×10
9
 cells per day, and, consequently, 
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an equal number of cells must die by apoptosis in order to maintain cellular homeostasis. 
Therefore, it was not surprising that deregulation of apoptosis could lead to an accumulation 
of living cells and contribute to tumor development (Cotter, 2009). Members of the Bcl-2 
family and many other oncogenes and tumor suppressor genes, such as Myc and TP53, were 
implicated in the regulation of apoptosis in different types of cancers, including breast cancer. 
Deregulated apoptosis may also be the leading cause of cancer therapy chemoresistance. 
I.2.2 Breast cancer 
Different types of cancers are named based on the part of the body from which they originate. 
Thus, breast cancer is a pathological condition in which this uncontrolled cell division has 
started in breast tissue (Figure 3). Breast cancer is, in turn, classified into different types based 
on the cellular location of the tumor. 
 
Figure 3- The anatomy of breast tissue. (www.breastcancersource.com) 
Breast cancer is the most common malignant tumor in women, both worldwide and in the 
high-income countries, as defined by the World Bank. According to estimations by the WHO, 
breast cancer leads to more than 500,000 deaths per year in the world, and belongs to the top 
ten mortal diseases. Besides the large number of cases, breast carcinoma is also among the 
most heterogeneous types of cancer: first, in terms of the clinical course and classification; 
second, in terms of the cellular and genetic background of the actual tumor mass. Successful 
treatment of patients with primary breast carcinoma is therefore highly dependent on an in-
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depth characterization of each individual case. A more profound examination, e.g. concerning 
the local spread, the tissue of origin (ductal, lobular, and others), the estrogen and 
progesterone hormone receptor status, as well as a detailed histochemical characterization of 
expressed proteins like Her2/Neu, P53, Bcl-2 (apoptosis marker) or the proliferation marker 
Ki67, is today's clinical standard (Urruticoechea et al., 2005). Several genes such as BRCA1/2, 
PTEN, LKB1, ATM, PALB2 and CHEK2 are also proposed to contribute to breast cancer 
(Domchek and Weber, 2006; Renwick et al., 2006; Rahman et al., 2007). 
I.2.2.1 Breast cancer and apoptosis 
Since 1990, death rates from breast cancer have decreased by over 25%. This is at least in part 
due to the improved use of adjuvant chemotherapy. Apoptosis plays a key role in the 
development of the normal breast. Normal breast development is controlled by a balance 
between cell proliferation and apoptosis, and there is strong evidence that tumor growth is not 
just a result of uncontrolled proliferation, but also of reduced apoptosis. Dysregulation 
overrides many of the normal checkpoint pathways and leads to expansion of neoplastic cells. 
The balance between proliferation and apoptosis is also crucial in determining the overall 
growth or regression of the tumor  in response to chemotherapy, radiotherapy and, more 
recently, hormone treatments (Reed, 1999; Tamm et al., 2001). Apoptosis is induced by 
chemotherapy, endocrine treatment, and radiotherapy. When these treatments fail, 
dysregulation of apoptosis may be a cause for cancer development. Genes and proteins that 
control apoptosis have become targets for manipulation in order to enhance the cancer cell 
death. Understanding these relations could allow individually tailored treatments to maximize 
tumor regression and increase the efficacy of treatment. It could also help answer why some 
tumors fail to respond, thereby indicating new routes of drug development (Parton et al., 
2001). 
I.3 RNA interference 
RNA interference (RNAi) is a universal and evolutionary conserved post-translational 
regulatory system within living cells that helps to control which, and in what way, genes are 
active. RNAi has been discovered as a mechanism that can be exploited as a valuable 
experimental tool, leading to efficient sequence-specific gene silencing, thus allowing 
functional gene analysis (Fire et al., 1998). In the RNAi process, double-stranded RNA 
(dsRNA), homologous to the target locus, can specifically inactivate gene function (Hannon, 
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2002). RNA interference can be experimentally achieved by delivery of a synthetic small 
interfering RNA (siRNA) (Elbashir et al., 2001a) or by a plasmid DNA vector containing 
sequence coding for a small hairpin RNA (shRNA) (Brummelkamp et al., 2002; Elbashir et 
al., 2002; Paddison et al., 2002). Both siRNAs and shRNAs are currently being tested in 
clinical trials against conditions in which an overactive gene needs to be silenced (Check, 
2007).   
I.3.1 RNA interference mechanism 
The RNAi mechanism is the disruption of a gene‟s expression by a double stranded RNA 
(dsRNA) in which one strand is complementary to a section of the gene‟s mRNA. Figure 4 
presents an overview of the RNAi pathway. In an RNAi assay, dsRNAs are introduced into 
the cell. In the cytoplasm, they are processed by an enzyme of the Dicer family into 21-23 bp 
fragments called small interfering RNAs (siRNAs) (Elbashir et al., 2001b). Next, the siRNAs 
are used as targeting co-factors by RISC, which binds to and destroys complementary mRNAs 
catalytically. In fruit flies and mammals, the antisense strand is directly incorporated into the  
RISC and activates it. In worms and plants the antisense strand might first be used in an 
amplification process, in which new long dsRNAs are synthesized, which are again cleaved 
by Dicer. Finally, antisense siRNA strands guide the RISCs to complementary RNA 
molecules, where they cleave and destroy the cognate target RNA. This process leaves the 
genomic DNA intact but suppresses gene expression by RNA degradation. Key components 
of the RNAi pathway have also been implicated in the processing of the novel class of 
molecules called microRNAs (miRNAs), which are emerging as key endogenous regulators of 
gene expression during development (Elbashir et al., 2001b). MicroRNAs are initially 
transcribed as long RNAs, and are processed in the nucleus by the RNase III enzyme Drosha 
into a pre-miRNA of about 70 nucleotides (nt). The pre-miRNA, which forms an imperfect 
hairpin structure, is bound by Exportin-5 and exported into the cytoplasm where Dicer further 
processes it into a mature, single-stranded miRNA. MiRNAs from animals appear to regulate 
gene expression by binding to partially complementary sequences in the 3′ untranslated 
regions (UTRs) of target mRNAs and suppressing translation (Lund et al., 2004). 
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Figure 4- The RNAi pathway. Sources for RNA-induced gene silencing include (a) dsRNAs, 
(b) miRNAs, (c) shRNAs and (d) chemically synthesized siRNAs. Dicer processes dsRNAs, 
pre-miRNAs and shRNAs into siRNA/miRNA duplexes containing 5′ monophosphate groups 
and 2-nt 3′ overhangs. Next, these duplexes are unwound and incorporated into the 
appropriate effector complex (RISC/miRNP). The degree of pairing between the 
siRNA/miRNA and the target mRNA appears to determine whether silencing occurs via 
mRNA degradation or translational repression. 7 mG, 7-methyl guanine; AAAA, poly-
adenosine tail (Kittler and Moss, 2006). 
I.3.2 Applications of RNA interference 
The success of this basic methodology has led to the rapid, widespread adoption of RNAi as 
the new method for targeted gene silencing in a wide variety of experimental systems from C. 
elegans to human cells. RNAi is prominent in functional genomics research for two reasons. 
The first one is the physiological role of RNAi in gene regulation. The second reason is that 
screens resulting in the inhibition of target genes by RNAi can be applied on a broader scale, 
thus allowing the rapid identification of genes whose modulation contributes to changes in 
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cellular processes and pathways (Mello and Conte, 2004). RNAi has become widely used for 
knocking-down the expression of a specific target gene by a posttranscriptional silencing 
mechanism, thereby allowing phenotypic analysis of gene function in cells of different 
organisms (Kamath and Ahringer, 2003; Kiger et al., 2003; Lettre et al., 2004). Unfortunately, 
the high cost of genome-wide libraries of chemically synthesized 21mers necessary for RNAi 
(Figure 5a, b) in human cells (Elbashir et al., 2001b) has, so far, limited screens to small 
targeted libraries of several hundred genes, at most (Aza-Blanc et al., 2003). The alternative 
technology of short hairpin RNAi (Figure 5e, f) has been applied in different assays, such as 
luminescence assays (Zheng et al., 2004). 
The high activity, long protein half-life and high endogenous expression of some genes might 
make it difficult to generate detectable loss-of-function phenotypes by RNAi, especially in the 
case of certain enzymes, as residual activity might be sufficient for the enzymes to fulfil their 
cellular roles (Boutros and Ahringer, 2008). Importantly, using multiple siRNAs for the same 
target gene theoretically increases silencing from 70% to 95%. Although the concept of using 
such a pool of siRNAs (Figure 5c-d) is attractive for achieving a higher probability of strong 
silencing in fewer experimental samples, it is assumed that the silencing performance of the 
pool is at least as good as the individual siRNAs (Echeverri and Perrimon, 2006). 
Previous studies have shown that RNAi screening studies are powerful approaches to identify 
genes involved in biological processes, such as cell division, proteasome- and p53 function 
(Lettre et al., 2004; Nollen et al., 2004; Kittler et al., 2007; Rines et al., 2008). Recently, 
RNAi techniques have been used to study entire sets of kinases and phosphatases that regulate 
various signaling pathways involved in cell survival and apoptosis (MacKeigan et al., 2005; 
Mattila et al., 2008). In addition, RNAi screening by time-lapse imaging of living cells 
provides a great advantage in discriminating the primary immediate phenotype caused by 
gene suppression from a secondary cellular response (Neumann et al., 2006). The beneficial 
or detrimental effects of siRNA or shRNA inhibition of specific genes and the induction of 
phenotypic changes in affected cells are analyzed using various means, including 
pharmacological, histological and biochemical assays. 
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Figure 5-  Silencing reagents for RNAi screens in mammalian cells. Publicly available 
libraries of silencing reagents enable genome-scale RNAi screens in mammalian cells using 
the following types of molecules. (a) The most widely used small interfering RNAs (siRNAs) 
are synthetic molecules with a canonical structure that consists of a 19-bp duplex with 2-base 
overhangs at the 3' ends and an unmodified RNA backbone (these are supplied by various 
companies, for example Ambion, Dharmacon and Qiagen). (b) Alternatively, synthetic 
siRNAs with non-canonical siRNA structures (an siRNA with no overhangs is shown) and/or 
a modified RNA backbone are also available (for example, the Stealth siRNAs from 
invitrogen) (c) siRNAs can also be used as low-complexity pools of <10 molecules that target 
the same transcript (for example, SmartPools from Dharmacon). (d) High-complexity pools of 
siRNA-like molecules (esiRNAs) can be synthesized by in vitro digestion of long dsRNAs 
using bacterial RNase III or Dicer. (e) As an alternative to these synthetic molecules, vector-
based library reagents are also available, all expressing short hairpin RNA (shRNA) 
constructs, which are usually delivered virally. Most vector-based shRNA libraries carry a 
single RNase III-driven shRNA insert. (f) A new vector design now offers an RNase II- or 
RNase III-driven shRNA insert within a backbone from a known miR, producing so-called 
'shRNAmiRs' that enter the RNAi pathway as pri-miRNAs, upstream from conventional 
shRNAs. CDS, coding sequence (Echeverri and Perrimon, 2006). 
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I.4 Reverse transfection cell array 
The application of microarray-based technology for molecule genetic analysis has 
revolutionized the study of certain aspects of gene function. DNA microarrays allow high-
throughput analysis of gene expression, and thus a technology for identifying genes whose 
modulation are potentially involved in particular cellular processes. However, DNA 
microarrays do not provide a direct analysis of gene product function within the living cell, 
and such functional analyses are often performed singly, on a one by one basis.  
In 2001, Ziauddin and Sabatini established a method for miniaturization of cell-based 
functional studies called “reverse transfection cell microarray” (Figure 6) (Ziauddin and 
Sabatini, 2001). The term reverse was used because the order of addition of the target cells 
and DNA to the surface is reversed compared to conventional transfections. This technology 
allows spatially restricted transfection without the use of wells by immobilizing nucleic acids 
complexed together with a transfection reagent in a gel matrix spot.  Adherent cells growing 
on top of such printed spots will take up the nucleic acids deposited in the spot, while cells 
growing between the spots will not be transfected. As contact between DNA and the target 
cells is a requirement for successful transfection, immobilizing DNA particles prior to the 
attachment of target cells can lead to higher transfection efficiencies (Webb et al., 2003).  
Merging of surface-mediated transfection technology with DNA microarray technology 
provided a method for simultaneously screening large numbers of genes using surface-
mediated transfection of arrayed libraries of cDNAs, siRNAs and shRNAs (Ziauddin and 
Sabatini, 2001; Mousses et al., 2003; Wheeler et al., 2005; Mannherz et al., 2006; Moffat et 
al., 2006).  
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Figure 6- Reverse transfection cell array scheme. This method involves spotting of 
siRNAs, shRNAs or cDNA vectors, complexed with a transfection reagent and a reporter 
plasmid such as pEYFP on standard glass slides. These slides are then exposed to cells in 
culture, allowing transfection of the nucleic acids into the cells in contact with the spots.  
Thereafter, a cell-based assay, for example the presence of apoptotic bodies, is used to 
monitor the effects caused by the transfected molecule. 
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I.5 Aim of this project 
The aim of this project was the identification and characterization of human genes with 
possible capability to inhibit apoptosis in normal and tumorigenic cell lines.  
In the first part of the study, in order to identify novel human anti-apoptotic factors in non-
tumorigenic human embryonic kidney (HEK293T) cells, a loss-of-function screen through 
transient transfection of shRNA-coding plasmids targeting a set of poorly characterized genes, 
was the method of choice. In the second part of the study, an RNA interference approach 
using siRNAs was used to identify anti-apoptotic candidates among genes which were over-
expressed in human breast cancer patients who were resistant to chemotherapy. In this study, 
MCF7 breast cancer cells were selected as a cancer model to study the effect of silencing of 
the genes.  
Loss of function screen in HEK293T cells would help to uncover novel factors involved in 
apoptosis pathways while screen of candidate genes in the second part may lead to 
identification of genes important for survival and proliferation of cancer cells leading to 
possible new strategies for treatment of breast cancer. 
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II Materials and methods 
II.1 Materials 
II.1.1 Instruments 
REAGENT PURCHASED FROM 
7900 HT Fast Real Time PCR Systems  Applied Biosystems, Forster city, USA 
ABI PRISM 3100 Genetic Analyzer, 16 Capillary  
DNA Sequencer  
Applied Biosystems, Forster city, USA 
ABI PRISM 7900 Sequence Detection System  Applied Biosystems, Forster city, USA 
Automatic developing machine  Amersham, Freiburg, Germany  
BD FACS Array™ Bioanalyzer System BD Bioscience, San Jose, USA 
BD FACSCanto II workstation  BD Bioscience, San Jose, USA 
BD FACSCalibur workstation  BD Bioscience, San Jose, USA 
Beckman GS-6KR centrifuge Beckmann, Wiesloch, Germany  
Biofuge 13R, Biofuge Fresco, Biofuge pico Heraeus, Kendro, Hanau, Germany  
Centrifuge 5810 R  Eppendorf, Hamburg, Germany  
Bacterial incubator Heraeus, Kendro, Hanau, Germany  
Cell culture incubator Köttermann, Hänigsen, Germany 
Cell culture microscope Carl Zeiss, Jena, Germany 
Centrifuge 580R Eppendorf, Hamburg, Germany 
Coverslip  R. Langenbrinck, Teningen, Germany 
CCD camera ORCA-ER-1394 Hamamatsu Photonics K.K, Japan 
EL800 Universal Microplate Reader BIO-TEK, VT, USA 
Electrophoresis power supply E-C Apparatus Corporation, USA  
Fluorescence Microscope Axioplan Carl Zeiss, Jena, Germany 
GenePix 4000A microarray scanner  Axon Instruments, CA, USA  
GSA- and SS34- Rotor DuPont, Boston, USA 
Heat Block QBT2 Grant Instruments/CLF, Emersacker  
Incubation chamber Hybri-Well Sigma-Aldrich, Munich, Germany 
LB-940 Mithras Multilabel Reader  Berthold Technologies, Bad Wildbach, Germany  
Mastercycler PCR-Maschine  Eppendorf, Cologne, Germany 
Micro-centrifuge NeoLab Laborbedarf, Heidelberg, Germany  
Mini-Protein 3 gel and electrophoresis system  Bio-Rad Laboratories, Munich, Germany  
Multifuge 3SR Heraeus, Kendro, Hanau, Germany 
NanoDrop ND-100 Spectrophotometer NanoDrop Technologies, San Diego, USA 
Omnigrid Microarrayer GeneMachines, San Carlos, USA 
Poly-L-lysine-coated Poly-Prep Slides Sigma-Aldrich, Munich, Germany  
QuadriPERM plates  Vivascience, Hannover, Germany  
Speedvac concentrator apparatus  Eppendorf, Cologne, Germany  
Spotting pins  TeleChem International, Sunnyvale, USA 
Thermomixer compact  Eppendorf, Cologne, Germany  
Unimax 1010 Shaker  Heidolph Instruments, Schwabach, Germany  
Vortex Scientific Industries Genie-2, New York, USA 
Water bath SW22 Julabo Labortechnik, Seelbach, Germany  
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II.1.2 Chemical reagents and general materials 
REAGENT PURCHASED FROM 
Acrylamide (30% w/v)/Bisacrylamide (29/1 
0.8%) 
Bio-Rad Laboratories, Munich, Germany 
Agarose Sigma-Aldrich, Munich, Germany 
Ammonium peroxydisulfate (APS) Sigma-Aldrich, Munich, Germany 
Ampicillin Sigma-Aldrich, Munich, Germany 
Bacto-agar Difco Laboratories, Detroit, USA 
Bovine serum albumin (BSA) Sigma-Aldrich, Munich, Germany 
Bacto-trypton Difco Laboratories, Detroit, USA 
Bacto-yeast -extract Difco Laboratories, Detroit, USA 
Bromphenol blue Sigma-Aldrich, Munich, Germany 
Blocking-Reagent Roche Diagnostics, Mannheim, Germany 
2-Mercaptoethanol Roche Diagnostics, Mannheim, Germany 
Chloroform Merk, Darmstadt, Germany 
Cy3-streptavidin Amersham Bioscience, Buckinghamshire, UK 
Chloramphenicol Sigma-Aldrich, Munich, Germany 
Desoxynucleotide –Set (dATP, dGTP, dCTP, 
dATP) 
Roche Diagnostics, Mannheim, Germany 
Dithiothreitol (DTT) Sigma-Aldrich, Munich, Germany 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Munich, Germany 
Ethylenediaminetetraacetic acid-disodium salt 
(EDTA) 
Merk, Darmstadt, Germany 
Ethanol Merk, Darmstadt, Germany 
Ethidiumbromide Sigma-Aldrich, Munich, Germany 
Etoposide Sigma-Aldrich, Munich, Germany 
Formamide Merk, Darmstadt, Germany 
FasL BD Bioscience, Heidelberg, Germany 
Gelatin Sigma-Aldrich, Munich, Germany 
Glycerin Roth, Karlsruhe, Germany 
Halt™ protease and phosphatase inhibitor single-
use cocktail, EDTA-free 
Thermo Scientific, Rockford, USA 
Kanamycin Roche Diagnostic, Mannheim, Germany 
Magnesiumchloride Merk, Darmstadt, Germany 
Methanol Merk, Darmstadt, Germany 
Milk powder Sigma-Aldrich, Munich, Germany 
Na2HPO4 Merk, Darmstadt, Germany 
NaH2PO4 Merk, Darmstadt, Germany 
NaOH Merk, Darmstadt, Germany 
Natriumacetat Merk, Darmstadt, Germany 
Natriumchloride Merk, Darmstadt, Germany 
Natriumcitrate Merk, Darmstadt, Germany 
Methanol Merk, Darmstadt, Germany 
Nuclease free water Ambion, Austin, USA 
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Propidium iodide (PI) Invitrogen, Karlsruhe, Germany 
QIAzol Qiagen, Hilden, Germany 
Rainbow Molecular Weight Marker Amersham, Freiburg, Germany 
SDS Sigma-Aldrich, Munich, Germany 
TEMED Bio-Rad Laboratories, Munich, Germany 
Tris-(hydroxymethyl)-aminomethane (Tris) Sigma-Aldrich, Munich, Germany 
Tris-Base Sigma-Aldrich, Munich, Germany 
Triton-X100 Sigma-Aldrich, Munich, Germany 
Tween 20 (Polyoxy-ethylen-sorbitan-
monolaurate) 
Sigma-Aldrich, Munich, Germany 
TNFα Calbiochem, Darmstadt, Germany 
Vectashield mounting medium containing DAPI Vector Laboratories, Burlingame, CA, USA 
z-VAD-FMK Calbiochem, Darmstadt, Germany 
II.1.3 Cell Culture 
REAGENT SOURCE 
DMEM Gibco BRL/ Invitrogen, Karlsruhe, Germany 
Foetal calf serum (FCS) Biochrom, Berlin, Germany 
Phosphate buffered saline (PBS) Gibco BRL/ Invitrogen Karlsruhe, Germany 
Penicillin 1000u/ml 
Streptomycin100µg/ml 
Gibco BRL/ Invitrogen Karlsruhe, Germany 
II.1.4 Kits 
ITEMS SOURCE 
Absolute qPCR Green Mixes ABgene, Epsome, UK  
All Prep RNA Protein Kit Qiagen, Hilden, Germany 
Caspase-Glo3/7 assay Promega, Karlsruhe, Germany 
Caspase-Glo8 assay Promega, Karlsruhe, Germany 
Caspase-Glo9 assay Promega, Karlsruhe, Germany 
Big Dye Terminator Sequencing Kit  Applied Biosystems, Forster City, USA 
Effectene Transfection Reagent Qiagen, Hilden, Germany 
ECL + Western Blot Detection Kit 
 
GE Healthcare Europe GmbH, Freiburg, 
Germany 
ECL Hyperfilm GE Healthcare Europe GmbH, Freiburg, 
Germany  
Plasmid Mini Kit Qiagen, Hilden, Germany 
Dual-Luciferase Assay Reporter System Promega, Karlsruhe, Germany 
RNeasy mini Kit Qiagen, Hilden, Germany 
siPORT™ NeoFX™ Ambion, Austin, USA 
Pierce BCA Protein Assay Ki t − Reducing 
Agent Compatible Kit. 
Thermo Scientific, Rockford, USA 
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II.1.5 Antibodies 
ANTIBODIES SOURCE DILUTIONS 
APC anti-human TNF receptor 1 BD Bioscience, Heidelberg, 
Germany 
1:200 
Mouse IgG1 antibody BD Bioscience, Heidelberg, 
Germany 
1:1000 
PE anti-human CD95 BD Bioscience, Heidelberg, 
Germany 
1:1000 
Rabbit anti-human PPP1R15B Sigma-Aldrich, Munich, Germany 1:500 
Mouse anti-human P53 Prof. Dr. H. Zentgraft DKFZ, 
Heidelberg 
1:2000 
Mouse anti-human Lamin B1 Santa Cruz Biotechnology, CA, 
USA 
1:1000 
Mouse anti-human GAPDH Calbiochem, Darmstadt, Germany  1:5000 
Anti-rabbit IgG, HRP-linked 
Antibody  
Cell Signaling Inc, Danvers, USA  1:5000 
Anti-mouse IgG, HRP-linked 
Antibody  
Cell Signaling Inc, Danvers, USA 1:5000 
SAv-APC (Streptavidin-
Allophycocyanin 
BD Bioscience, Heidelberg, 
Germany 
1:200 
 
II.1.6 sh-RNAs and plasmid DNA 
SH-RNAS AND PLASMID DNA SOURCE 
Expression Arrest ™ shRNA library Open Biosystems,Huntsville,USA.Table5 
(supplementary) 
sh-Birc4 (1) Open Biosystems, Huntsville, USA. 
V2HS_94574 
sh-Birc4 (2) Open Biosystems, Huntsville, USA.  
V2HS_94579 
sh-Birc5(1) Open Biosystems, Huntsville, USA.  
V2HS_94583 
sh-Birc5(2) Open Biosystems, Huntsville, USA. 
V2HS_94582 
sh-Birc7(1) Open Biosystems, Huntsville, USA. 
V2HS_200958 
sh-Birc7(2) Open Biosystems, Huntsville, USA. 
V2HS_5714 
sh-TP53 Open Biosystems, Huntsville, USA. 
V2HS_93615 
sh-LMNB1 Open Biosystems, Huntsville, USA. 
V2HS_62672 
sh-GFP Open Biosystems, Huntsville, USA. RHS4459 
pCMV6-XL5-CHMP5 OriGene,Technologies Inc, Rockville, USA 
pCMV6-XL5-Birc4 OriGene,Technologies Inc, Rockville, USA 
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pCMV6-XL5 OriGene,Technologies Inc, Rockville, USA 
NFκB-luc pGL3 Dr. Min Li-Weber DKFZ, Heidelberg (Li-Weber 
et al., 1998) 
pTK-RL Dr. Stefanie Heck DKFZ, Heidelberg 
pSUPEdL Pscherer et al., 2006 (Pscherer et al., 2006) 
FLIP cDNA expression Dr. Ina Lavrik Division of Immunogenetics, 
DKFZ Heidelberg 
pEYFP-C1 BD Biosciences Clontech, Palo Alto, CA, USA 
 
II.1.7 Oligonucleotides Primers 
PRIMER NAME SEQUENCE 
PGK1 forward 5'-AAGTGAAGCTCGGAAAGCTTCTAT-3' 
PGK1 reverse 5'-TGGGAAAAGATGCTTCTGGG-3‟ 
LAMINB1 forward 5'-CTGGAAATGTTT GCATCGAAGA-3' 
LAMINB1 reverse 5'-GCCTCCCATTGGTTGATCC-3' 
GAPDH Qiagen, Hilden, Germany (no sequence 
available) (Cat. #: QT00079247) 
CHMP5 forward 5'-GGAAAGCGAAACCCAAGG-3', 
CHMP5 reverse 5'-TGGATTCTGCTCTACTGTCCAC-3' 
BIRC4 forward 5'-GGCGCGAAAAGGTGGACAAGTCCT-3' 
BIRC4 reverse 5'-CCTTATTGATGTCTGCAGGTACAC-3' 
FLIP forward 5'-GCTCACCATCCCTGTACCTG-3' 
FLIP reverse 5'-CAGGAGTGGGCGTTTTCTT-3' 
PPP1R15B forward 5'-TCGGTACAGCGTGACGTTC-3' 
PPP1R15B reverse 5'-GCGATCCTCATCACCACTTAT-3' 
U6 sequencing primer 5'-GACTATCATATGCTTACCGT-3' 
 
II.1.8 siRNAs 
SI-RNA NAME SOURCE 
CHMP5-siRNA 1 Qiagen, Hilden, Germany, SI00728098 
CHMP5-siRNA 2 Qiagen, Hilden, Germany, SI03187905 
Birc4-siRNA Qiagen, Hilden, Germany, SI00299446 
Birc5-siRNA Qiagen, Hilden, Germany, SI00299453 
Birc7-siRNA Qiagen, Hilden, Germany, SI02645111 
GFP-siRNA Ambion, Austin, USA, AM4626 
GFP-siRNA Qiagen, Hilden, Germany, SI3650346 
“All stars“ negative control Qiagen, Hilden, Germany, SI1027280 
FLIP-siRNA Qiagen, Hilden, Germany, SI00057218 
PPP1R15B-siRNA 1 Qiagen, Hilden, Germany, SI03045462 
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PPP1R15B-siRNA 2 Qiagen, Hilden, Germany, SI03050257 
PPP1R15B-siRNA 3 Qiagen, Hilden, Germany, SI03087245 
PPP1R15B-siRNA 4 Qiagen, Hilden, Germany, SI03079923 
107 siRNA pool for screening Qiagen, Hilden, Germany,Hilden, Germany. 
Prof. Michael Boutros, DKFZ, Germany (Table 
6 Supplementary) 
 
II.1.9 Cell lines 
CELL LINES CELLULAR ORIGIN SOURCE 
HEK293T  embryonic kidney HEK293T cells transformed with 
the SV40 Large T Antigen 
(ATCC CRL-1573) 
MCF7 breast Human breast cancer cell line 
(ATCC HTB-22) 
EVSAT breast Prof. Peter Altevogt DKFZ, 
Germany 
MDA-MB231 breast Prof. Peter Altevogt DKFZ, 
Germany 
MDA-MB435 breast Prof. Peter Altevogt DKFZ, 
Germany 
SKBR3 breast Prof. Peter Altevogt DKFZ, 
Germany 
T47D breast Prof. Peter Altevogt DKFZ, 
Germany 
HDQP1 breast Prof. Peter Altevogt DKFZ, 
Germany 
II.1.10 Media, Solutions and Buffers 
MEDIA, SOLUTIONS AND BUFFERS COMPONENTS 
APS 10% APS w/v in ddH20 
LB Medium 1 % (W/V) Bacto-Trypton 
0.5 % (W/V) Bacto-Yeast –Extract 
1 % (W/V) NaCl 
In H2O, pH = 7.5 
Autoclave at 121°C and 1000hPa for 20 min 
S.O.C. Medium 
 
2% trypton 
0.5% yeast extract 
10 mM NaCl 
2.5 mM KCL 
10 mM MgCL2 
10 mM MgSO4 
20 mM glucose 
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10x PBS 
 
137 mM NaCl 
27 mM KCl 
100 mM NaH2PO4 
17 mM KH2PO² 
dissolve in ddH2O 
1x TBS-T 
 
20 mM Tris-Base 
137 mM NaCl 
3.8 ml 1M HCl 
0.1% (v/v) Tween 20 
dissolve in 1l ddH20 
5x Loading buffer 
 
100 mM EDTA 
30% (v/v) glycerine 
0.25% (w/v) bromophenolblue 
 dissolve in ddH2O 
20% SDS 
 
20% SDS (w/v) 
dissolve in ddH20 
2x Laemmli buffer 
 
50 mM Tris/HCl pH=8.0 
2.4% w/v SDS 
8% glycine 
0.2% w/v bromphenol blue 
2.5% v/v β-mercaptoethanol 
5x SDS-PAGE running buffer 
 
25 mM Tris-Base 
200 mM glycine 
10% (w/v) SDS 
ddH20 
10x Western blot buffer 
 
25 mM Tris-Base 
192 mM Glycine 
20% v/v methanol (added when preparing 1x 
buffer) 
ddH20 
BSA- blocking buffer 3% BSA in PBS 
FACS staining buffer (DNA staining) 0.1% (w/v) sodium citrate, pH 7.4 
0.1% (v/v) Triton X-100 
50 μg/ml propidium iodide 
in PBS 
FACS buffer (Receptor staining) 5%FBS 
0.1% sodium azide 
in PBS  
Resolving gel buffer 1.5M Tris-Base 
10% (w/v) SDS 
ddH20 
PH= 8.8 
Stacking gel buffer 0,5M Tris-Base 
10% (w/v) SDS 
ddH20 
PH=6.8 
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Milk-blocking buffer 10% Milk powder in TBS-Tween (0.1%)  
Stripping buffer 
 
100 nM β-Mercaptoethanol 
2% SDS 
62.5 nM Tris-HCl, pH=6.7 
ddH20 
RIPA buffer 0.5% natrium deoxycholate (w/v) 
1% Nonidet P-40(v/v)  
0.1% SDS(w/v) 
ddH20 
 
II.1.11 Antibiotics 
NAME STOCK 
CONCENTRATION 
SOLVED IN CONCENTRATION IN 
MEDIUM 
Ampicillin 100 mg/ml H2O 100 µg/ml 
Chloramphenicol 100 mg/ml Ethanol 100 µg/ml 
Kanamycin 100 mg/ml H2O 100 µg/ml 
 
Materials and methods 
 
 26 
II.2 Methods 
II.2.1 General molecular biology methods 
II.2.1.1 Transformation in competent bacteria  
One Shot® TOP10 chemically competent E.coli DH10B (Invitrogen, Karlsruhe, Germany) 
were used to amplify plasmid DNA. 50μl of electro-competent E.coli were thawed on ice, 
mixed with the complete ligation reaction and incubated on ice for 30 minutes. Thereafter, the 
bacteria were shifted to 42°C for 60 s and briefly equilibrated on ice. 250-300μl of SOC 
medium was then added and cells were incubated for 1 h at 37°C with shaking (800 rpm). The 
suspension was plated onto LB-agar plates containing the respective antibiotic and incubated 
overnight at 37°C. In order to propagate the cultures, either single colonies were picked or 
frozen glycerol stocks were thawed and inoculated into 10ml LB medium with antibiotic, and 
shaken overnight at 37°C. For storage of bacteria, a bacterial culture was grown in culture 
medium to an OD of 0.8 (measured at 600nm). Thereafter, 500µl of the bacterial culture was 
combined together with 500µl glycerol and subsequently frozen at –80°C. 
II.2.1.2 Mini-preparation of plasmid DNA 
E.coli containing the plasmid of interest was inoculated in 8ml LB medium, including the 
appropriate antibiotics, and grown overnight at 37°C in a shaking incubator (200 rpm). 
Plasmid DNA was extracted using the Qiagen Plasmid Mini Kit. First, the bacteria was  
harvested by centrifugation for 15 min at 3500 rpm and re-suspended in 250μl buffer P1 
containing 0.1mg/ml RNase A. Thereafter, 250μl of lysis buffer P2 was added and the tube 
inverted gently 4–6 times. 350μl neutralization buffer N3 was then added to the tube and 
mixed again by inversion. The resulting lysate was centrifuged for 10 minutes at maximum 
speed in a tabletop microcentrifuge (13,000 rpm). The supernatant from this centrifugation 
was added to a QIAprep spin column containing 2ml collection tube and centrifuged for one 
minute by 13,000 rpm. The flow-through was discarded and the column bound plasmid DNA 
was washed using 500μl of buffer PB, followed by centrifuging for one minute (13,000 rpm). 
After discarding the flow-through, the column was washed with 750μl of PE-buffer, followed 
by centrifuging for 1 minute (13,000 rpm). Thereafter, the column was placed into a clean 
1.5ml microcentrifuge tube, 50 µl of water was added and incubated at room temperature for 
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one minute. The DNA was then eluted by centrifugation for 1 minute (13,000 RPM). 
Quantification of the DNA samples were carried out on a Nanodrop spectrophotomer using 
the DNA measurement setting. 
II.2.1.3 RNA isolation and quality assessment 
Total RNA was extracted from cells (1×10
6
) in culture. The cells were harvested, washed with 
PBS and centrifuged for 5 minutes at 3000 rpm. The cell pellet was lysed in 1ml lysis reagent 
reagent (QIAzol), incubated for 5 minutes at RT, then 300μl chloroform was added. The 
mixture was mixed thoroughly and incubated for another 5 minutes at RT. Thereafter the cell 
lysate was centrifuged for 15 minutes in a pre-cooled centrifuge at 4°C at 13,000 rpm. The 
aqueous phase was placed into a fresh tube and mixed with an equal volume of 70% ethanol, 
transferred to a RNeasy spin column and centrifuged for one minute at 13,000rpm. The flow-
through was discarded and 700μl of wash buffer RW1 was added, and the centrifugation and 
flow through removal procedure repeated. The same procedure was repeated using 500μl RPE 
wash buffer. In the end, the RNeasy spin column was placed in a new collection tube and the 
RNA eluted in 50μl nuclease free water by centrifugation at 13,000 rpm for one minute. 
Quantification of the RNA sample was carried out using the Nanodrop spectrophotomer using 
the RNA measurement settings (A260 / A280 ratio). 
II.2.1.4 Protein isolation with RIPA buffer 
RIPA buffer enables the extraction of cytoplasmic, membrane and nuclear proteins and is 
used many applications, including reporter assays, protein assays, immunoassays and protein 
purification. RIPA buffer does not contain protease or phosphatase inhibitors. However, if 
desired, protease and phosphatase inhibitors (Halt™ Protease and phosphatase inhibitor) can 
be added to the RIPA buffer (10μl/ml) just before use, in order to prevent proteolysis and to 
maintain the phosphorylation state of the proteins. For protein extraction, cultured cells were 
harvested, washed in PBS, and centrifuged (800 rpm, 10 min, RT) in order to isolate the 
pelleted cells. These cells were then lysed in100μl of RIPA buffer incubated for 20 minutes 
on ice and centrifuged at 13,000 rpm for 15 minutes to remove particulate material. The 
supernatant containing the extracted protein was transferred to a new microcentrifuge tube 
and stored at -20 °C. 
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II.2.1.5 Protein quantification (BCA Protein Quantification) 
Total protein concentration was measured using the Pierce BCA Protein Assay. The BCA 
assay is based on the reduction of Cu+2 to Cu+1 by protein in an alkaline medium followed 
by colorimetric detection of the cuprous cation using bicinchoninic acid (BCA).  
BCA working reagent was prepared by mixing 50 parts of BCA Reagent A to 1 part of BCA 
Reagent B. 20μl of the BSA standards or samples were plated into single wells of a 96 well 
microtiter plate well.  Thereafter, 100μl of BCA working reagent was added, the plate shaken 
for 30 seconds and then placed in a 37°C incubator for 30 minutes. The plate was then cooled 
to room temperature and the absorbance read at 562nm. A standard curve of absorbance 
versus micrograms of standard protein was prepared, and the protein concentration of the 
samples was determined from this graph. 
II.2.1.6 DNA sequencing 
Sequencing of DNA was performed according to the modified dideoxy-sequencing method of 
Sanger (Sanger et al., 1977). The reaction mix (Big Dye Terminator Cycle Sequencing Kit) 
contained fluorescent labelled dideoxy-derivates for all of the four nucleotides (Rosenblum et 
al., 1997), dNTPs, a specific oligonucleotide primer for the DNA to be sequenced and a 
thermostable DNA polymerase. Due to the initial denaturation step during the reaction, 
sequencing of dsDNA is possible. In this assay, 250ng of plasmid DNA and 100pmol DNA 
sequencing primer was mixed with 3µl of Big Dye and adjust to 10µl with water. DNA cycle 
sequencing was then performed using a thermocycler. The cycling conditions for the PCR 
amplification were: 2 minutes at 96°C, followed by 25 cycles of 5 s at 96°C, 10 s at 55°C, and 
4 minutes at 60°C. After PCR amplification, the samples were precipitated at RT with 2.5 Vol. 
100% ethanol and 1/10 Vol. 3M natrium-acetate, washed once with 70% ethanol, dried and 
resuspended in 10μl formamide. An ABI3100 Capillary DNA Sequencing Apparatus was 
used for DNA separation and sequence detection. 
II.2.1.7 Quantitative real time -PCR primer design 
PCR primers for quantitative real-time (qRT)-PCR experiments were designed with the 
primer design tool from Roche Applied Science: „Universal probe library‟ 
(https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000). Primer pairs 
were chosen which included at least one intron sequence in the PCR product in order to 
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distinguish between contaminating genomic DNA amplicons, and those resulting from 
amplification of the correct cDNA  template. 
II.2.1.8 cDNA synthesis 
Reverse transcription (RT) is the transcription of RNA into single strand complementary 
DNA (cDNA). For the RT reaction, in a final volume of 20μl, 1 μg of total RNA (in 8μl 
RNase-free water) was used together with 2μl of 5x 1st strand buffer (250 mM Tris-HCl, pH 
8.3, 375 mM KCl, 15 mM MgCl2) and 1μl (10 units) DNaseI, and incubated for 20 minutes at 
RT to allow digestion of genomic DNA. Thereafter, 3μl of  Master Mix1, which contained 
equal parts of 25mM EDTA, dNTP mix (10mM dNTP´s each), and 300ng/μl random hexamer 
primers, was added to the mix and incubated in a thermocycler, first for 10 minutes at 65°C 
and then for 10 minutes at 25°C. This step removed secondary structures; heat inactivated the 
DNaseI and allowed the annealing of primers to the RNA.  5μl of  master mix 2 containing 5x 
1st strand buffer, 0.1 M DTT and nuclease free water at a ratio of 2:2:1 was then added.  The 
mixture was incubated initially at 42°C for 2 minutes, then 1μl of reverse transcriptase and 
0.2μl of T4 gene P32 protein were added to the mixture and further incubated for 50 minutes 
at 42°C. Thereafter,  the  reaction was heat inactivated for 10 minutes at 95°C. 
II.2.1.9 Real-Time PCR analysis 
The PCR reaction mixture consisted of 6μl SYBR Green PCR mixture, 100nM forward and 
reverse primer and 2μl cDNA templates in a reaction volume of 12μl. A standard curve 
consisting of a dilution series of the Stratagene qPCR Human Reference cDNA (1:1, 1:2, 1:4, 
1:8, 1:16, 1:32, 1:64, 1:128), was used to determine the efficiency of the PCR reaction. To 
quantify cDNA templates obtained from RNA samples, real-time PCR was performed in a 
7900 HT Fast Real-Time PCR System (Applied Biosystems, Forster City, USA) with the 
following settings: 2 minutes at 50°C, 95°C for 15 minutes, then 40 cycles of 15 seconds at 
95°C, 1 minute at 60°C. Final steps comprised 15 seconds at 95°C, 15 seconds of 60°C, and 
15 seconds at 95°C. The heating ramp between the last two steps was increased to 20 minutes 
to obtain a melting curve of the final qRT-PCR products. This was necessary because SYBR 
Green fluorescence products may also be derived from side products such as primer dimers. 
Calculation of efficiency and relative quantification was performed using the housekeeping 
genes (phosphoglycerate kinase 1 (PGK1), lamin B1 (LMNB1) and Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as reference.  
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II.2.1.10 Western blot analysis 
For 10% SDS-PAGE gel 10% acrylamide/bisacrylamide in resolving buffer buffer for the 
resolving part and 5% acrylamide in stacking buffer for the stacking part were prepared. 
0.06%(w/v) ammoniumpersulphate and 0.1%(v/v) N,N,N´,N´-tetramethylethylendiamine 
(TEMED) were added to the gel solution to induce polymerization. Transfected cells were 
harvested by centrifugation (800 rpm, 10 minutes, room temperature (RT)). 6µg of the protein 
samples (see II.2.1.4 and II.2.1.5) were boiled in Laemmli buffer (1:1) for 5 minutes and 
subsequently loaded onto the slots of the gel. In addition, a protein size maker was also 
included. Electrophoresis of the protein gel was applied for 45 minutes at 160V and 70mA. 
The electrophoretic transfer of polypeptides from the polyacrylamide (PAA) gel to a 
polyvinylidene floride (PVDF) membrane was performed by using a wet gel transfer 
apparatus. The PVDF membrane was briefly activated in 100% methanol and soaked for 5 
minutes in Western blot buffer for 10 minutes. The PAA gels were carefully removed from 
the electrophoresis chamber, the stacking gel was cut and the gel was soaked 3 minutes in 
Western blot buffer. The Western blot „sandwich‟ was assembled and the transfer was carried 
out for 2h at 100V and 250mA in ice-cold Western blot buffer. For protein detection with 
antibodies, the membrane containing the separated polypeptides were placed in a tank and 
washed with washing buffer (15 minutes) followed by milk-blocking buffer for 1h at RT. 
After blocking, the membrane was incubated with diluted primary antibody over night at 4°C. 
After washing (3x10 minutes), the membrane was incubated with the secondary antibody 
conjugated with horse radish peroxidase for 1h at RT. After a further set of membrane 
washings (3x10 minutes), the blots were ready for enhanced chemiluminescence (ECL) 
protein detection (ECL Western Blot Detection Kit). The ECL substrate was prepared and the 
blot incubated with the solution for 1 minute in the dark at RT. The solution was then drained 
off, the membrane placed in a plastic foil to prevent drying, placed in a X-ray cassette and 
exposed to ECL film (Hyperfilm-ECL
™
). The exposure time of the film was between 10 
seconds and 5 minutes. 
II.2.1.11 Immunostaining of fixed cells 
At 72 hours after transfection (see II.2.3.3), cells which had been grown on slides were 
washed in PBS (5 minutes) and fixed with 4% para-formaldehyde in PBS. Thereafter, the 
samples were permeabilized and blocked in 0.2% Triton X-100/PBS with 10% blocking 
serum for 1hour, then incubated with mouse monoclonal anti-P53 (1:2000) or mouse 
Materials and methods 
 
 31 
monoclonal anti-Lamin B (1:1000;) antibodies diluted in 1% blocking serum/PBS by 37ºC for 
1h. After three washes (each time 5 minutes) with PBS, the cells were incubated with 
secondary antibody (1:5000), then washed again in PBS and air-dried. One drop of 
Vectashield mounting medium containing DAPI (staining of nuclei) was added and the slides 
were covered by coverslips. Fluorescence images were acquired by fluorescence microscopy  
using a CCD camera. 
II.2.2 Cell culture 
II.2.2.1 Cell maintenance 
Cell lines were maintained at 37°C and 5% CO2 in the following media: HEK293T, MCF-7, 
SKBR3, MDA-MB 231 in DMEM with 1g/l D-glucose (Invitrogen) supplemented with 10% 
fetal bovine serum (FBS), 100 units/ml penicillin and 100μg/ml streptomycin. All cells were 
routinely passaged every 2-3 days cells and diluted 1:6 in fresh medium. 
II.2.2.2 Reverse transfection cell array 
Reverse transfection was based on the protocol published by Ziauddin et al. (Ziauddin and 
Sabatini, 2001; Mannherz et al., 2006). Genes of interest were targeted using shRNA 
plasmids from the Expression Arrest ™ shRNA library. Expression ArrestTM shRNA was 
cloned into the pSHAG-MAGIC2 (pSM2) retroviral vector. This vector has a Murine Stem 
Cell Virus (MSCV) backbone and can be used for transient transfection. The vector contains 
different element such as U6 promoter and chloramphenicol/kanamycin bacterial selection 
marker. “Expression Arrest™ short hairpin” RNA constructs are expressed as human 
microRNA-30 (miR-30) primary transcripts. The “Expression Arrest™ Human” shRNA 
collection is provided in 96-well microtiter plates containing frozen stock cultures of E. coli 
(DH10bpir116) in LB broth with 8% glycerol and chloramphenicol (50μg/ml).After preparing 
the plasmids (II.2.1.2), 0.6μg pEYFP plasmid, Bax overexpression plasmid and 0.6μg of each 
shRNA plasmids (Expression Arrest ™ shRNA) (II.1.6), and 1.5μl Enhancer (included in 
Effectene Transfection Kit)  were added to 15μl EC buffer (included in Effectene Transfection 
Kit) containing 0.1 M sucrose. The mixture was incubated for 5 min at room temperature. 
Subsequently, 5μl Effectene was added and, again, incubated for 10 min at room temperature. 
A 1× volume of 0.4% (w/v) gelatin was mixed with the solution in order to complete the 
transfection master mix. The DNA–gelatin solution was arrayed in quadruplicate onto poly-L-
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lysine-coated Poly-Prep slides using the Omnigrid microarrayer and SMP15B spotting pins. 
Dot spacing was 1000μm, mean spot diameter was 600μm for all experiments. Slides were 
stored at room temperature for up to four weeks in a dry and sterile atmosphere until further 
processing. For transfection, slides were placed in QuadriPERM plates, overlaid with 2.2 × 
10
6
 HEK293T cells, and cultured in DMEM supplemented with 10% (v/v) fetal bovine serum, 
100 U/ml penicillin, and 100μg/ml streptomycin for 48 hrs. Cells were then fixed for 60 min 
at room temperature in 3.7% (w/v) paraformaldehyde in phosphate buffered saline (PBS). 
Fixed cells were permeabilized (0.1% sodium citrate (w/v), 0.1% (v/v) Triton X-100) in PBS 
for 5 min, washed two times for 5 min in PBS, overlaid with Vectashield mounting medium 
containing DAPI and covered with a coverslip (24 × 40 mm). The slides were scanned with a 
GenePix 4000A microarray scanner in order to evaluate transfection efficiency and EYFP 
expression. Morphologic and nuclear changes were assessed using an Axioplan fluorescence 
microscope. Fluorescence images were acquired on the fluorescence microscope by using the 
CCD camera ORCA-ER-1394 (Mannherz et al., 2006) (Figure 6, see section I.4). 
II.2.2.3 Standard transfection of HEK293T cells 
Chemical transient transfections using Effectene transfection reagent (Qiagen), siPORT™ 
NeoFX™ (Ambion) and respective amounts of plasmid DNA or siRNA were performed in 24 
or 96 well plates. Effectene-based transfections were carried out in 24 well plates using 4×10
4 
cells per well and 100ng/μl plasmid DNA in a final volume of 400μl culture medium. 
Plasmids expressing sequence verified short hairpin RNAs against 288 human poorly 
characterized genes were selected from the Expression Arrest ™ shRNA library (Open 
Biosystems, see Table 5 Supplementary). Plasmids were isolated using the QIAprep Spin 
Miniprep Kit and quantified by spectrometry. In shRNA experiments, a plasmid coding for a 
shRNA against firefly Luciferase (Pscherer et al., 2006), GFP and an expression vector 
containing pEYFP, were used as negative control, whereas shRNAs targeting Birc4, Birc5, 
Birc7 (II.1.6) were used as positive controls. Ectopic expression was performed for CHMP5, 
Birc4 using a pCMV6- expression vectors with pCMV6-XL used as negative control. 
Reverse transfection using siPORT™ NeoFX involves the simultaneous transfecting and 
plating of cells. siPORT™ NeoFX transfection agent and siRNA are mixed, incubated, 
distributed to culture wells, and overlaid with cells. Transfection complexes are active and 
stable in the presence of serum; therefore, in the absence of a cellular stress response, there is 
no need to remove or replace media after transfection.  In the this study, siPORT™ NeoFX™-
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based transfections were carried out in 96 well plate using 6×10
3 
cells per well in a final 
volume of 100μl culture medium or 24 well plate using 4×104 cells per well and 50nM siRNA 
in a final volume of 500μl culture medium. Different siRNAs targeting GFP were used as 
negative control whereas siRNAs against Birc4, Birc5, Birc7 or FLIP were used as positive 
controls (II.1.8). Two different siRNAs targeting the coding region (siRNA1-CHMP5) or the 
3' UTR-region (siRNA2-CHMP5) of CHMP5 were used for CHMP5 knock-down 
experiments. 
II.2.2.4 Transfection of MCF7 and other breast cancer cells 
For screening in breast cancer cells, 107 siRNAs ((II.1.8) Qiagen, human siRNA library) were 
used for transfection. Transient transfections of MCF7 cells were carried out in 96-well plates, 
using 6×10
3 
cells per well, siPORT™ NeoFX™ transfection reagent and respective amounts 
of si-RNAs (50nM) in a final volume of 100μl culture medium; or 24 well plate using 4×104 
cells per well and 50nM siRNA in a final volume of 500 μl culture medium. Different siRNAs 
targeting GFP, luciferase and All Star Negative siRNA Control (Qiagen) were used as 
negative controls, whereas siRNAs against Birc4, Birc5, and Birc7 were used as positive 
controls. Four different siRNAs targeting the coding region of PPP1R15B (siRNA-1-
PPP1R15B, siRNA-2-PPP1R15B, siRNA-3-PPP1R15B, siRNA-4-PPP1R15B) were used for 
validation experiments (II.1.8). 
II.2.3 Expression arrays 
II.2.3.1 Illumina expression array 
Three major expression profiling platforms (Affymetrix, Agilent, Illumina) are commercially 
available. In this study the Illumina platform for expression profiling has been used (service is 
available at core facility of DKFZ). Illumina‟s BeadArray technology is based on 3µm silica 
beads that self assemble in microwells on either of two substrates: fiber optic bundles or 
planar silica slides. When randomly assembled on one of these two substrates, the beads have 
a uniform spacing of ~5.7 µm. Each bead is covered with hundreds of thousands of copies of 
a specific oligonucleotide representing one unique cDNA sequence that act as the capture 
sequences in the Illumina assay. Characteristics of the BeadArray technology are quality 
control of every single array and the high feature- redundancy (>20x average) providing high-
confidence results. The BeadChip array format used by Illumina utilizes either 6, 8, or 12 
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different arrays on a glass slide, which are processed simultaneously. In the current study, we 
applied 6 arrays/chip, each representing > 48,000 probe sequences. 
II.2.3.1.1 RNA preparation and quality analysis 
Total RNA from HEK293T cells at 24h, 48h, or 72h after transfection with pSM2-sh-CHMP5, 
pCMV6-CHMP5, sh-Luc or pCMVX plasmids were isolated using an RNeasy kit as 
described in (II.2.1.3). The quality of total RNA was tested on an Agilent 2100 Bioanalyzer 
using the total RNA Nano Chip Assay (Agilent Technologies GmbH, Germany). 
II.2.3.1.2 cRNA synthesis, purification and labeling  
In this step, 250 ng of total RNA was used for complementary DNA (cDNA) synthesis 
(II.2.1.8), followed by an amplification/ labelling step (in vitro transcription) to synthesize 
biotin-labeled cRNA according to the MessageAmp II aRNA Amplification kit (Ambion Inc., 
Austin, TX). Biotin-16-UTP was purchased from Roche Applied Science (Penzberg, 
Germany). The cRNA was column-purified according to TotalPrep RNA Amplification Kit‟s 
manual (Ambion, Austin, USA) and eluted in 60μl of water. The quality of cRNA was 
controlled using the RNA Nano Chip Assay on an Agilent 2100 Bioanalyzer and 
spectrophotometrically quantified using a NanoDrop spectrophotometer.  
II.2.3.1.3 Probe labeling and Illumina Sentrix BeadChip array hybridization 
Biotin-labelled cRNA samples for hybridization on Illumina Human Sentrix-6 BeadChip 
arrays (Illumina, Inc.) were prepared according to the protocol of Illumina's recommended 
sample labeling procedure (Eberwine et al., 1992). Hybridization was performed at 58°C, in 
GEX-HCB buffer (Illumina Inc., San Diego, USA) at a concentration of 50 ng cRNA/μl, 
unsealed in a wet chamber for 20h. Spike-in controls for low, medium and highly abundant 
RNAs were added, as well as mismatch control and biotinylation control oligonucleotides. 
The microarrays were washed twice in E1BC buffer (Ambion Inc., Austin, TX) at room 
temperature for 5 minutes. After blocking for 5 minutes in 4 ml of 1% (w/v) Blocker Casein 
in phosphate buffered saline Hammarsten grade (Pierce Biotechnology Inc., Rockford, IL), 
array signals were developed by a 10-minutes incubation in 2 ml of 1μg/ml Cy3-streptavidin 
solution and 1% blocking solution. After a final wash in E1BC buffer, the arrays were dried 
and scanned. 
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II.2.3.1.4 Scanning and data analysis 
Microarray scanning was done using a Beadstation array scanner, setting adjusted to a scaling 
factor of 1 and PMT settings at 430. Raw data extraction was performed using the Beadarray 
R package (svn release 1.7.0) from bioconductor.org. Next, outliers were removed when their 
expression value dropped below a threshold: the median + *MAD (median absolute deviation) 
expression of all negative control beads. Individual bead types were also flagged as filtered 
when their bead replicate count dropped below 17. All data were then used for the mean 
expression value calculations within Beadarray. Finally, a bead type was discarded when the 
bead type‟s filter flag was set across all samples. Data analysis was carried out by variance 
stabilizing and robust spline normalization of the remaining signals using the algorithms from 
the Lumi R package (release 1.1.0 from bioconductor.org). Subsequently, values of different 
time points were subtracted from values of the time point zero and related negative controls. 
The thresholds for individual samples were determined by calculating the median value of all 
values within one sample and subtracting or adding the 1.5-fold standard deviation from each 
median value. Values higher (up-regulated) or lower (down-regulated) than each threshold 
defined differentially regulated genes. 
II.2.3.2 Pathway analysis 
II.2.3.2.1 Comprehensive gene pathway analysis 
Analysis of the experimental results in the wide context of gene pathways or gene groups is an 
important step during data analysis. It helps to identify significant trends or changes in the 
data in a level above that of a single gene. Microarray data for gene expression patterns are 
mapped into gene or metabolic pathways with the help of the software Comprehensive Gene 
Pathway Analysis (CGPA) (Engel el al. in preparation). Pathway analysis with CGPA aims to 
identify the most discriminating gene pathways between two groups. For example, it helps to 
differentiate between two time points of equally treated samples in terms of relevant general 
biological processes or functions. 
After performing the analysis using R, the statistical programming language, and PHP 
(hypertext reprocessor programming), a scored pathway list is presented to the user. The 
scoring procedure includes significance tests, random permutations and multiple testing 
adjustments. Here, pathways are scored for the relevance as well as for their degree of 
modulation from the most activated pathway to the most inactivated pathway, discriminating 
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the two groups. The visualization takes shape in a webpage (Table 7, Supplementary data). 
II.2.3.2.2 Ingenuity pathway analysis 
For Ingenuity Pathways Analysis (IPA, www.Ingenuity.com), three lists of fold change values 
for the genes (24h, 48h, and 72h) differentially regulated by CHMP5 silencing were used. Up- 
and down-regulated genes, whose values were above a threshold of two fold standard 
deviations, were included in this analysis. More than 95% of these genes mapped to the 
Ingenuity software. The identified genes were sorted by the mapped genetic networks found 
in the Ingenuity database. Each potential network was given a score, which was a probabilistic 
fit between the number of affected genes in a given network and a list of biological functions 
stored in the Ingenuity Pathways Knowledge Base (IPKB). These scores were used to rank the 
networks. We restricted our analysis to those networks that had the highest rank. 
II.2.4 Functional analysis 
II.2.4.1 Apoptosis assay 
Apoptosis was assayed by flow cytometry using propidium iodide (PI) staining (Nicoletti et 
al., 1991). Cells from a 24-well microtiter plate were harvested, washed once with (PBS), 
resuspended in 100μl FACS staining buffer and incubated at 4°C for 6h in darkness. Finally, 
the DNA content present in the stained nuclei was determined by flow cytometry using the 
FACSArray Bioanalyzer System. 
In over-expression and rescue assays, apoptosis was induced in HEK293T cells by etoposide 
at a concentration of 25μg/ml and measured by PI staining using the FACSArray Bioanalyzer 
System. 
For the caspase inhibition assay, cells were transfected with shRNA expressing vectors and 
24h later were treated with the caspase inhibitor Z-VAD-FMK at a final concentration of
  
20µM, which was administered every 24h due to its instability. The cells were analyzed for 
apoptosis 72h after transfection by FACS analysis after PI staining of the nuclei. 
II.2.4.2 Cell viability assay 
The CellTiter-Glo
®
 Luminescent cell viability assay is a method of determining the number of 
viable cells in culture based on quantitation of the ATP present, an indicator of metabolically 
active cells. The Cell Titer Glo Luminescent Cell Viability Assay was used to verify the 
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viability of the transfected MCF7 cells in opaque-walled multiwell plates (Costar, Baar, 
Germany). 72h after transfection, 100μl of CellTiter-Glo® Reagent (Promega) was added to 
each well in order to measure the ATP content of the well. 100µl or 400 µl of the reagent was 
used to measure cell viability of transfected cells in the 96 or 24 well plate formats, 
respectively.  After 10 minutes incubation at RT on a shaker (350rpm), fluorescence intensity 
was measured using a luminometer. Each assay was performed in triplicate. An integration 
time of 0.25 seconds per read was applied. 
II.2.4.3 Cell cycle analysis 
Fluorescence-activated cell sorter (FACS) analysis was performed to determine cell cycle 
kinetics. Transfected cells in each well, were stained with 400µl of FACS staining buffer and 
cellular DNA content of 10,000 events per sample was determined by flow cytometry using 
the FACS Canto II flow cytometer and was analyzed using the CellQuest™ software (Becton, 
Dickinson and Company). 
II.2.4.4 Proliferation assay 
The effect of a single gene knock-down on the proliferation of breast cancer cell line MCF7 
was assessed using the Click-iT™ EdU Flow Cytometry Assay Kit. EdU5-ethynyl-2´-
deoxyuridine is a nucleoside analogue to thymidine and is incorporated into DNA during 
active DNA synthesis. Briefly, 48h after transfection of cells with siRNAs (II.1.8), EdU was 
added to the medium and, after incubation for an additional 2h, the number of EdU-positive 
cells were measured for each experimental condition. Detection was based on a click reaction, 
a copper catalyzed covalent reaction between an azide and an alkyne. In this application, the 
EdU contained the alkyne, while the Alexa Fluor® 488 dye, Alexa Fluor® 647 dye, or Pacific 
Blue™dye contained the azide. Flow cytometry method was used for determining the 
percentage of the cells population that are in S-phase. 
II.2.4.5 Caspase activity measurement using the Caspase-Glo
®
  Assay                                                             
The Caspase-Glo
®
 Assay is a luminescent assay that measures caspase activity. Different 
types of caspases can be measured using the Caspase-Glo 3/7, Caspase-Glo 8 or Caspase-Glo 
9 Assay kits (Promega). The assay provides a proluminogenic caspase-8, 9 and 3/7 substrate 
in a buffer system optimized for caspase activity, luciferase activity and cell lysis.  
Materials and methods 
 
 38 
Luminescence is proportional to the amount of caspase activity present. Caspase activity 
assays were performed in 96 well plates. HEK293T and MCF7 cells were seeded 
(5×10
3
cells/well) and transfected with the respective siRNAs (II.1.8). After incubation for 24h 
or 48h, 100µl of Caspase-Glo reagents for different caspases (caspase-8, -9 and -3/7) were 
added to each well, incubated for 30 minutes, and the luminescent signal was measured using 
a luminometer. 
II.2.4.6 NF-κB luciferase reporter assay (dual-luciferase reporter assay) 
Genetic reporter systems are widely used to study regulation of eukaryotic gene expression. 
The term „dual‟ refers to the simultaneous expression and measurement of two individual 
reporter enzymes within a single system. The experimental reporter (firefly-luciferase) 
correlates with specific experimental conditions, while the activity of the co-transfected 
„control‟ (renilla-luciferase) provides an internal control that serves as a baseline for 
transfection efficiency. Normalizing the activity of firefly-luciferase to the activity of Renilla- 
luciferase minimizes experimental variability caused by differences in cell viability or 
transfection efficiency.  
The firefly-luciferase plasmid, containing four binding sites for NF-κB (Li-Weber et al., 1998), 
and the renilla-luciferase plasmid (pTK-RL pGL4.74, Promega) were used for transfection of 
cells. HEK293T cells (4×10
4
 per well) were seeded in 48-well plates. After 24h, the cells were 
transiently co-transfected with 100ng of NF-κB firefly- luciferase reporter vector and 2ng of 
renilla-luciferase reporter plasmid. After additional 24 h incubation, firefly and renilla- 
luciferase activities were assayed using the Dual-Luciferase Reporter System (Promega) and 
the luminescent signal was measured using a luminometer. Transfected cells grown in a 24-
well plate were lysed with 50μl of 1x passive lysis buffer (Promega) for 15 minutes at RT on 
a shaker (310 rpm). 120μl of each lysate were pipetted into a reader plate of the luminator in 
triplicate. The firefly-luciferase activity was measured by adding 100μl of LAR II reagent 
(Promega) to generate a stabilized luminescent signal. After quantifying the firefly 
luminescence, this reaction was quenched and the renilla-luciferase reaction was initiated by 
adding 100μl of Stop- and Glo reagent to the same tube. The Stop- and Glo reagent (Promega) 
produces a stabilized signal of the renilla-luciferase, which was measured in the luminometer. 
After normalizing the firefly-luciferase activity to the renilla-luciferase activity, a direct 
comparison of samples regarding NF-κB activity in the nucleus was possible. 
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II.2.4.7 Flow cytometric analysis of cell surface death receptor 
To detect expression levels of the cell surface receptors CD95 and TNFR1, 1×10
6
 cells were 
exposed to fluorochrome-conjugated antibodies against these proteins and analyzed by flow 
cytometry. Briefly, cells were harvested 24h after transfection and incubated in FACS buffer 
containing biotin-labeled anti-human CD120a, a monoclonal antibody against TNFR1 (1×10
6
 
cells, clone mAb TNFR1-B1), followed by SAv-APC (Streptavidin-Allophycocyanin, 1×10
6
 
cells), or  PE-conjugated anti-human CD95 monoclonal antibody (1×10
6
 cells, clone DX2) for 
30 min at 4°C in the dark. Isotope-matched antibodies were used as negative controls. After 
washing with FACS buffer, 10,000 cells were analyzed using a FACS Calibur flow cytometer 
equipped with CellQuest software. Results were expressed as median fluorescence intensities. 
II.2.5 Statistical analysis 
Data were expressed as mean values ± SD from two to five independent experiments.  
Statistical significance was determined using T-test to compare groups of data. P-values <0.05 
were considered as statistically significant.
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III Results 
In order to identify novel genes involved in apoptosis and cell viability, two sets of transient 
RNAi screens were performed; one screening in normal cells (HEK293T) (III.1) and another 
one in tumor cells (MCF7) (III.2). Loss-of-function screens applied in this study aimed to 
uncover the potential anti-apoptotic function of studied genes. To this aim, as the read-out of 
the screening experiments apoptosis and cell viability were measured. Further functional 
assays on candidates, including gene expression profiling and reporter gene assays, as well as 
receptor staining and cell cycle analysis were used to identify the pathway context of the 
candidate genes (III.1 and III.2). 
III.1 Short hairpin RNAi screen to in normal cells 
To screen for novel regulators of apoptosis, we performed an in vitro screen of 288 poorly 
characterized human genes using apoptosis as a read-out in HEK293T cells. Cells were 
transfected with single shRNA-coding plasmids targeting specifically the respective genes. 
After 72h, apoptosis was measured using fluorescent microscopy in the reverse transfection 
array method or PI staining and FACS analysis in direct transfection. 
III.1.1 Reverse transfection cell array technology 
In order to identify late apoptotic markers such as apoptotic bodies as a phenotype, reverse 
transfection was performed. In this study, pEYFP plasmid was used as a reporter for 
transfection efficiency of each individual shRNA (II.2.3.1). Knock-down efficiency was also 
examined using shRNAs against P53 and Lamin B1  followed by immunostaining (Figure 7). 
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Figure 7- Immunostaining of P53 and Lamin B1. HEK293T cells transfected by pEYFP 
expression vector, sh-Luciferas (sh-Luc, negative control), sh-P53 and sh-LaminB1, were 
stained by P53 and Lamin B1 antibodies 72h after transfection. DAPI was used to visualize 
the nuclei. P53 and Lamin B silenced cells are in dark areas upon immunostaining. 
In the initial attempt, which was a array-based assay to identify potential anti-apoptotic genes, 
288 shRNA coding plasmids were tranfected into HEK293T cells and an apoptotic phenotype, 
was evaluated by fluorescent microscopy 72h after transfection. In this assay, pEYFP and Bax 
expressing vectors were used as negative and positive controls, respectively and apoptotic 
bodies were considered as a specific late phenotype of apoptosis pathway activation (Figure 
8). 
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Figure 8- Identification of apoptotic cells by reverse tranfection cell arrays. An example 
of 96 shRNA out of 288. HEK293T cells transfected by shRNAs in 4 replicas. Negative and 
positive controls (pEYFP and Bax) are spotted in first and last rows of each slide. Apoptotic 
bodies are shown in Bax over-expressed and one of the shRNAs (H12) tranfected cells by 
arrows. 
In these array-based set of screens, due to the lack of enough apoptotic cells that could be 
observed under the microscope, no significant difference in the amount of dead cells was 
detected following silencing of genes. For example, only in one cluster of the shRNA 
transfected cells (shRNA clone H12) could a few apoptotic cells be detected, and only in a 
single spot out of four replicas. Therefore, due to these technical problems, screening of all 
288 shRNAs using the reverse transfection method did not result in the identification of a 
candidate that could be involved in apoptosis. It was observed that many dead cells, which 
were not tightly attached to the slides, were removed during the fixation procedures prior to 
microscopy for detection of apoptotic cells, making it difficult to compare the low number of 
apoptotic cells within different spots. Such observations led us to measure apoptosis as a read 
out by a more reliable method to consider larger amount of dead cells, which might appear 
following the silencing of individual genes. 
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III.1.2 Direct transfection and FACS analysis 
In this experiment, HEK293T cells cultured in microwells were directly transfected with 
shRNA-coding plasmids targeting specifically the genes of interest using effectene 
transfection reagent. About 72 hours after transfection, apoptosis was measured using PI 
staining and FACS analysis (Figure 9 B). Based on the reduced DNA content compared to the 
normal G1 population, sub-G1 cells were considered as apoptotic cells. The efficiency and 
reliability of transfection were determined by transfection of pEYFP expressing vector and the 
green fluorescent signal produced from this vector was visualized by-fluorescent microscopy. 
III.1.2.1 Optimization of the screening set-up 
An essential step for each screening is the definition of the best window, in which strong 
signals could be obtained with high sensitivity and low variability. Reproducibility is also an 
important factor that should be considered in each optimization procedure. 
In a particular assay, the dynamic range of the read-out is represented by difference between 
„baseline values‟, which are acquired by negative control genes and „positive hit values‟, 
which are obtained by positive control genes. The normalization of all data subsets from 
different plates into a single coherent data set is a great advantage of negative control included 
assays. Positive controls provide a quality control to ensure that the experiment was working 
properly.  
In the current study, several well-known apoptotic inhibitors such as Birc4, Birc5, and Birc7, 
and negative controls including pEYFP, pSuper- firefly luciferase (sh-Luc), pSM2-GFP (sh-
GFP) were examined in order to establish the experimental conditions. Different shRNA 
sequences targeting the above-mentioned positive control genes were tested for their silencing 
efficiency. The percentage of apoptotic cells observed upon silencing of putative apoptosis 
inhibitor genes is shown in Figure 9 A and B. 
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Figure 9- Apoptosis mediated by IAP genes silencing. (A) Percentage of apoptosis 
mediated by shRNAs targeting different sequences of positive controls Birc4 (1,2), Birc5 (1,2) 
and Birc7 (1,2) and negative controls pEYFP expression vector and shRNAs targeting 
luciferase and GFP. (B) Percentage of apoptotic cells (sub- G1 cells) of a single experiment 
measured by FACS analysis is shown. Birc 4, 5, 7 were used as positive controls and firefly 
Luciferase was negative control. 
Based on fold change increase in apoptosis obtained following silencing of the above 
mentioned positive controls, sh-Birc4(2) sh-Birc5(1) and sh-Birc7(2) were selected as proper 
positive controls and sh-Luc was selected as negative control to be used in the screening 
procedure.  
III.1.3 Short hairpin RNA (shRNA) screen to identify putative anti 
apoptotic genes 
The set of 288 shRNAs coding plasmids were transfected into HEK293T cells, and apoptosis 
was measured using PI staining and FACS analysis 72h after transfection. The relevant targets 
of those shRNAs that increased the level of apoptotic cells by more than 2.0 fold compared to 
the negative control (shRNA-luciferase), were defined as anti-apoptotic candidates (Figure 
10A). Four of the tested shRNA-clones, C6 (Opsin-1), F12 (CHMP5), H8 (EPAS2) and D9 
(termed “similar to KIAA1466”), fulfilled this demand. The identity of these shRNA-coding 
inserts for clones F12, H8 and D9 was verified by sequence analysis. Unfortunately, the C6-
shRNA sequence was found to be non-specific for Opsin-1. This sequence did not match with 
any known human gene or transcript sequence when compared to genome databases. 
Therefore, it was excluded from the validation assays. Moreover, replicate analysis of the 
shRNAs F12, H8 and D9 revealed a reproducible specific apoptotic effect only for clone F12 
clone (which targets CHMP5), such that about a two fold increase in the amount of apoptotic 
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cells (compared to the negative control sh-Luc) was observed  after transfection, which was 
similar to the effect seen by the  positive controls, (Figure 10 B).  Transfection of cells with 
plasmids coding shRNAs against known anti-apoptotic genes (Birc4, Birc5 and Birc7), 
resulted in a change of more than two fold in the amount of apoptotic cells when compared to 
the negative control sh-Luc. To test the specificity of the observed anti-apoptotic phenotype of 
CHMP5, further validation and functional characterization experiments were carried out 
including i. shRNA-knock-down, ii. over-expression, iii. rescue assays, and iv. measurement 
of caspase activities. 
  
Figure 10- Loss-of-function screening identifies CHMP5 as an anti-apoptotic candidate 
gene. (A) By screening 288 shRNAs targeting genes with unknown or poorly characterized 
function, CHMP5 was identified as an anti-apoptotic candidate. HEK293T cells were 
transfected with individual shRNA coding plasmids. 72h later, apoptosis was measured by PI 
staining and FACS analysis. Dashed line marks the value of the negative control (shRNA 
targeting firefly luciferase, used for normalization). (B) Fold change in apoptosis was 
confirmed by transfection of cells with individual shRNA coding plasmids targeting D9, H8 
and F12 (CHMP5), as well as Birc 4, 5, 7 (positive controls) and firefly luciferase (negative 
control). Error bars represent the standard deviation (SD) based on three independent 
experiments. 
 
III.1.4 Validation studies confirm the specificity of CHMP5 anti-apoptotic 
function 
III.1.4.1 siRNAs targeting different segment of CHMP5 RNA 
One major concern regarding RNAi is the proof of target specificity. Recent reports have 
demonstrated a possible risk for RNAi-induced off-target effects (Jackson et al., 2003). This 
phenomenon, potentially mediated by both the sense and antisense strands of siRNA or 
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shRNA duplexes, may lead to unspecific knock-down of genes (Snove and Holen, 2004; 
Tschuch et al., 2008). 
To exclude that possible off-target effects initiated the CHMP5-phenotype, we confirmed the 
shRNA-mediated CHMP5-phenotype by using two siRNAs directed against different 
segments of the CHMP5-mRNA. Both siRNAs increased the percentage of apoptotic cells 
(11% CHMP5-siRNA1 and 8.4 % CHMP5-siRNA2) when compared to a negative control 
(GFP-siRNA, 5.4 % Figure 11).  
 
Figure 11- Specificity of CHMP5 silencing effect. Induction of apoptosis in HEK293Tcells 
was confirmed by transfection of two different CHMP5-siRNAs (1 and 2) targeting different 
sites in the CHMP5 mRNA-sequence. Birc4-siRNA was used as positive control and GFP-
siRNA as negative control. Apoptosis was measured 72h after transfection by PI staining and 
FACS analysis. Error bars represent the SD based on three independent experiments. 
 
In addition, the silencing efficiency of shRNAs and siRNAs directed against CHMP5 was 
validated by quantitative real-time PCR measuring CHMP5 mRNA levels. Both shRNA-
coding plasmid and the two different siRNAs targeting CHMP5, reduced target mRNA levels 
by about 50% (Figure 12). Thus, the induced apoptotic phenotype seems to be resulted from 
specific silencing of CHMP5. 
Results 
 
 47 
 
Figure 12- Expression of CHMP5 in transfected HEK293T cells. The level of CHMP5 
mRNA was measured by qRT-PCR 48h after transfection and values were normalized to 
laminB1 and PGK mRNA levels, which were used as loading controls. Error bars represent 
the SD based on two independent experiments. 
 
III.1.4.2 Over expression and rescue assays 
To validate the anti-apoptotic function of CHMP5, we sought to perform over-expression and 
rescue assays. Ectopic expression of CHMP5 was carried out by transfecting CHMP5 
expression plasmid (pCMV6-CHMP5) into HEK293T cells. A chemical induction of 
apoptosis was done using etoposide (25 µg/ml) and apoptosis was measured (Figure 13A).  
72 hours after transfection, transfection of cells with pCMV6-CHMP5 (human or murine) or 
pCMV6-Birc4 reduced the number of apoptotic cells to about 50% for Birc4 and 40% for 
human CHMP5 and murine CHMP5 when compared to the negative control experiments 
(cells transfected with empty pCMV6 expression vector). Therefore, the over-expression of 
CHMP5 increased the survivability the cells emphasizing that CHMP5 plays a role in 
modulating apoptosis.  
Rescue assays were performed by co-transfection of cells with either the human or the murine 
CHMP5-cDNA expression vector with the CHMP5 sh-RNA coding plasmid (see Figure 13B). 
The shRNA sequence targets human CHMP5 mRNA with perfect complementary, whereas in 
case of the murine CHMP5, three mismatches in base-paring are present (Supplementary 
Figure 30) which disturb the targeting effect of the sh-RNA. The anti-apoptotic effect 
observed after transfection of the human CHMP5 expression vector could be rescued by co-
transfection of shRNA-CHMP5. However, in case of the transfection with murine CHMP5 
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expression vector, the human CHMP5-shRNA was not able to revert the decreased apoptotic 
phenotype. Taken together, these experiments define a specific anti-apoptotic function for 
CHMP5. 
 
Figure 13- Validation of CHMP5 function in apoptosis by overexpression and rescue 
studies. Over-expression of human and murine CHMP5 (pCMV6-CHMP5) as well as Birc4 
(positive control) reduce apoptosis induced by etoposide. HEK293T cells, seeded in 24 well 
plates, were transfected with cDNA-expressing vectors: pCMV6 (negative control), Birc4 
(positive control), human or murine CHMP5 (pCMV6-CHMP5). For rescue experiments, cells 
were co-transfected with human shRNA-CHMP5 and cDNA vectors for human or murine 
CHMP5 (pCMV6-CHMP5), and co-transfection of pCMV6 and sh-Luc as negative control. 
24h after transfection, cells were treated with 25 µ/ml etoposide. Apoptosis was measured 
72h after transfection by FACS analysis after PI staining. Error bars represent the SD based 
on two independent experiments. 
 
III.1.5 Functional characterization of CHMP5 
III.1.5.1 CHMP5-silencing induces caspase activation 
In order to confirm induction of apoptosis after silencing of CHMP5, downstream factors such 
as caspase-3/-7 were studied. In this experiment, HEK293T cells were transfected with 
shRNA-coding plasmids targeting Birc4, CHMP5, or firefly-luciferase and the activity of 
caspases-3/-7, key mediators of apoptosis, was measured by the caspase-Glo3/7 assay 
(Promega). Compared to the negative control (sh-Luc), the activity of caspase-3/7 was 
considerably higher in Birc4- (positive control) and CHMP5-silenced samples (2.95 and 2.75 
folds, respectively) (Figure 14 A). In addition, inhibition of caspase activity was examined by 
incubating transfected cells either in the presence or absence of the pan-caspase inhibitor Z-
VAD-FMK. The inhibition of caspase activity by Z-VAD-FMK led to a clearly reduced 
percentage of apoptotic cells in CHMP5-shRNA transfected cells (6 % versus 12 %) (Figure 
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14 B), as well as in the positive control cells transfected with sh-Birc4 (9 % versus 17 %). 
These data demonstrate that the observed apoptotic phenotype mediated by CHMP5-silencing 
is dependent on caspase activity, supporting the conclusion that CHMP5 plays a role in 
apoptotic pathways through caspase-3/7. 
 
Figure 14- Involvement of caspase activity in CHMP5 RNAi mediated apoptosis. (A) 
Caspases-3/7 activation obtained by CHMP5 silencing. Cells were transfected with shRNA 
targeting luciferase (sh-Luc as negative control), CHMP5 (sh-CHMP5) or Birc4 (sh-Birc4 as 
positive control) and activity of caspase-3/7 was determined by the caspase-Glo 3/7 
luminescence assay. Results are displayed as fold changes in caspase activity relative to sh-
Luc related value, which was set to one. (B) Inhibition of apoptosis by pan-caspase inhibitor 
Z-VAD-FMK. Transfected cells were treated with 20 µg/ml pan-caspase inhibitor Z-VAD-FMK 
12h after transfection and incubated for 72h. Thereafter apoptosis was measured by PI 
staining and FACS analysis. Error bars represent the SD based on three independent 
experiments. 
 
To verify whether the activation of caspase-3/7 in CHMP5-silenced cells is a result of the 
extrinsic apoptotic pathway, specific caspase-8 activity was assayed. As shown in Figure 15A, 
caspase-8 activity in HEK293T cells transfected with siRNAs, which target either CHMP5 or 
the well known caspase-8 inhibitor FLIP, was about 1.6 fold higher than the negative control. 
These data clearly indicate an involvement of caspase-8 activation in the apoptotic effect 
induced by CHMP5 silencing. In contrast, caspase-9 activation after CHMP5 siRNA 
transfection was only 1.2 fold higher when compared to the activity observed after 
transfection of the GFP-specific negative control. In addition, caspase-9 activity initiated by 
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the silenced positive control (Birc4) showed a 1.4 fold increase over the negative control 
(Figure 15B). Knock-down efficiency in each experiments was measured by qRT-PCR 
(Figure 31 supplementary). 
 
Figure 15- Activation of caspase-8 and-9 by CHMP5 silencing. Caspase-8 (A) and 9 (B) 
activities (fluorescence units) were measured in HEK293T cells 24h after transfection with si-
CHMP5, si-FLIP and si-Birc4 (positive controls) or si-GFP (negative control). Error bars 
represent the SD of two independent experiments each based on triplicate raw data. 
 
Taken together, these observations suggest that CHMP5 silencing induces apoptotic pathway 
by caspase cascade activation mainly through caspase-8 initiated caspase-3/7 activation 
leading to the apoptosis phenotype. 
III.1.6 Expression array analysis 
A DNA microarray experiment shows the expression levels of thousands of genes at a single 
time point and this provides a snapshot view of genome-wide expression patterns. 
To investigate the potential regulatory effects of CHMP5 upon a broad spectrum of signaling 
pathways, the effect of CHMP5 knock-down or overexpression 24h, 48h and 72h after 
transfection were examined by genome wide expression array profiling using Illumina Human 
Sentrix-6 BeadChip arrays. Gene expression profiles of HEK293T cells after CHMP5 
silencing or overexpression were compared to the expression profiles of relevant negative 
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controls (sh-Luciferase and pCMV6). Quantitative real time PCR of the RNA used for gene 
expression profiling was performed to measure the CHMP5 RNA level at 24h, 48h and 72h 
after transfection both by sh-CHMP5 and by sh-luc or pCMV6-CHMP5 and pCMV6 empty 
vector. Lists of regulated gene transcripts for different time points (24h, 48h, and 72h) after 
CHMP5 modulation were generated following processing of the array raw data. All 
information about expression array analysis are available in in the Gene Expression Omnibus 
(GEO) dataset (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17003). Regulated 
transcripts, which were potentially affected by CHMP5 silencing, were selected if they were 
ranked within the first 100 most affected genes in at least two of the three time points 
measured, based on their fold change. Down-regulated genes are listed in Table 1 and up-
regulated genes are shown in Table 2. Similar analysis, performed in HEK293T cells over 
expressing CHMP5, are shown in Table 8 (see supplement). In all individual time-point 
comparisons, we identified CHMP5 itself among the most affected transcripts: down- 
regulated-rank 1 for loss-of-function-24h, down-regulated-rank 2 for loss-of-function-48h, 
down-regulated-rank 5 for loss-of-function-72h, as well as up-regulated-rank 1 for gain of 
function-48h and 72h. 
Table 1- Down-regulated genes revealed by expression array analysis following CHMP5 
silencing at different time points.  
* Genes belonged to the list of 100 most affected genes in more than one time point. 
Regulated genes in both 24h and 48h (A), 24h and 72h (B), 48h and 72h(C) time points are 
shown. 
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Table 2- Up-regulated genes upon CHMP5 silencing at different time points. 
*Genes belonged to the list of 100 most affected genes in more than one time point. 
Regulated genes in both 24h and 48h (A), 24h and 72h (B), 48h and 72h(C) time points are 
shown. 
 
Gene ontology analysis of all selected genes upon revealed a high frequency of apoptosis-
associated factors (SMS, APBB3, MSRB2, DNAJB1, GADD45B, DDIT3, GADD45A, ATF3, 
PPP1R15A, CYR61, AXUD1, RND3, ADM, NFKBIA and MOAP1).  
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III.1.7 Pathway analysis 
III.1.7.1 Comprehensive gene pathway analysis after CHMP5 modulation 
identifies relevant signaling cascades 
To identify CHMP5-affected signaling pathways, comprehensive gene pathway analysis 
(CGPA) software (II.2.3.2.1) was applied to the expression array data (III.1.6). The high-
ranked pathways affected in both silenced and over-expressed cells, were grouped into the 
following categories: cancer, protein degradation, metabolism and signaling (Table 3 and 
Table 7 (A, B) Supplementary). 
   Table 3- Processes affected by the modulation of CHMP5 expression 
 
III.1.7.2 Ingenuity pathway analysis and relevant NF-κB factors 
Ingenuity Pathway Analysis (IPA) is a powerful tool to elucidate pathways and networks 
connected to a gene of interest, based on the expression profiling data (see methods). A more 
detailed analysis using IPA revealed that several regulated genes are mainly implicated in the 
NF-κB network (Figure 16). Most of these genes are involved in cellular processes such as 
apoptosis. Several of these genes, such as TSC22D3, TNFRSF12A, SGK, DDIT3, GADD45B 
can function as regulators of NF-κB and others such as TRIB3, ADM, SMAD7, SLIT2, PEA15, 
SLC7A1 and RGS16, can be regulated by NF-κB. 
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Figure 16- NF-κB network related factors affected by CHMP5 silencing. Related genes 
were identified by Ingenuity pathway analysis (IPA). 
Based on these findings, we assessed the ability of CHMP5 to modulate NF-κB activity using 
NF-κB-luciferase reporter construct assays. Figure 17 shows that NF-κB activity is inhibited 
by CHMP5 over-expression (luciferase reporter activity value = 0.7) compared to the 
pCMV6-empty vector control (luciferase reporter activity value = 1.6), whereas silencing of 
CHMP5 resulted in an increased NF-κB activity (luciferase reporter activity values of 2.3 and 
1.6 for sh-Luc and sh-CHMP5 transfected cells, respectively). 
 
Figure 17- NF-κB reporter assay. NF-κB-firefly luciferase activity relative to renilla luciferase 
is shown in normalized light units (Rlu). HEK293T cells were transfected with shRNA CHMP5 
plasmid or pCMV6-expression plasmid for  . PCMV6 empty vector and sh-luciferase were 
used as negative controls. Relative luciferase activity was measured 24h after transfection. 
Error bars represent the SD of two independent experiments, each based on triplicate raw 
data. 
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III.1.8 Death receptor expression is influenced by CHMP5 
Our expression array and pathway analyses showed that NF-κB-associated genes and 
apoptotic related genes are regulated upon CHMP5-silencing. In addition, previous studies 
showed that CHMP5 deficiency induces up-regulation of multiple signaling pathways that are 
related to the lack of internalized receptor degradation (Shim et al., 2006). Likewise, caspase 
activity data in this study indicated that the loss of CHMP5 is inducing apoptosis by the 
extrinsic pathway. Therefore, we investigated the expression of the two death receptors 
TNFR1 and CD95, both known to be upstream regulators of the NF-κB signaling pathway 
and also involved in extrinsic apoptosis activation. Surface expression of death receptor 
TNFR1 on the cell membrane was measured by FACS analysis of HEK293T cells in which 
the CHMP5 gene activity had been modulated. Surface expression of TNFR1 was 
significantly increased (p-value = 0.0002) upon CHMP5 silencing, whereas it was reduced 
compared to negative controls (p-value = 0.005) following overexpression of CHMP5 (Figure 
18 A, B). In contrast, surface expression of the CD95 (Apo-1/Fas) receptor, another cell death 
receptor of the TNFR family, was not significantly changed by silencing or overexpression of 
CHMP5 (Figure 18 C). Our results suggested that CHMP5 might specifically influence the 
expression of TNFR1, but not that of CD95 receptor on the cell membrane surface. 
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Figure 18- Cell surface expression of death receptors TNFR1 and CD95 . HEK293T cells 
were transfected with shRNA-or overexpression-plasmids for CHMP5. ShRNA-luciferase and 
empty vectors (pCMV6) were used as negative controls. Cells labelled by fluorescent 
antibodies detecting TNFR1 or CD95 were counted by flow cytometry 24h after transfection. 
Flow cytometry analysis (one out of five experiments is exemplified in A) shows differences in 
median values of surface expression of TNFR1 by silencing (*, P < 0.0002 versus sh-Luc) or 
overexpression of CHMP5 (**, P < 0.005 versus pCMV6) (A, B) and (C) no difference in 
CD95 surface expression. Error bars represent the SD based on five independent 
experiments. 
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III.2 SiRNA screen in breast cancer cells 
In order to identify novel regulators of cell death in breast cancer cells, we performed an in 
vitro screening in MCF7 cells using siRNAs against 107 transcripts that had been found over-
expressed in breast cancer patients resistant to chemotherapy. Cell viability was used as read-
out in this project. 
III.2.1 Background of selected genes for RNAi screening 
Recently a comprehensive study investigated the potential of a gene expression signature, to 
predict the response of patients to the triple chemotherapy with GEDoc (gemcitabine, 
epirubicin and docetaxel) (Thuerigen et al., 2006). Gene expression analysis performed in this 
study was based on RNA samples from small tissue biopsies, obtained from primary breast 
tumor tissue. Breast cancer patients were classified based on their response to the therapy. 
According to the clinical behavior, patients were considered as responders only if they had a 
pathological complete remission (pCR) after primary systemic chemotherapy. Patients with 
residual tumor cells at surgery, either resulting in pathological partial remission (pPR) or 
pathologically no change (pNC), were considered as non-responders. 
It had been hypothesized that among genes, which are up-regulated in pNC compared to pCR, 
cell death inhibitors can be found that might be responsible for proliferation and survival of 
cancer cells and cause a negative response to therapy. For this purpose, Significant Analysis 
of Microarray (SAM) analysis was performed between series of gene expression data of nine 
pCR and six pNC samples to identify significantly differentially expressed genes between the 
two patients‟ groups. Out of 376 differentially expressed genes, 151 were up-regulated in the 
pNC group. Based on available siRNAs against these transcripts, we performed a loss-of- 
function screen of 107 up-regulated genes in pNC to identify those that have an impact on the 
reduction of cell viability and proliferation upon silencing. Our ultimate goal was to identify 
genes, which are potentially involved in survival pathways responsible for resistance to 
therapy in patients, who were classified as exhibiting no change (pNC) after chemotherapy. 
III.2.2 Optimization of the screening set-up 
Screening in breast cancer MCF7 cells was performed using siRNAs. The reason for using 
siRNAs in this screen was because of the availability of a genome-wide siRNA library 
(Qiagen) in house, which provided the opportunity to pick up the siRNAs targeting the 
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candidate genes of this library. For optimization procedures, different negative controls, such 
as “Allstar siRNAs”, and siRNAs directed against firefly luciferase and GFP were tested to 
obtain the baseline of the assay read-out. SiRNAs targeting Birc4, 5 and 7 were also tested to 
optimize the best condition for screening. In this experiment, MCF7 cells were cultivated in 
white 96 well plates and tranfected directly using the above-mentioned siRNAs. At 24, 48 and 
72h after transfection, Cell Titer Glo reagent (Promega) was added to each well and the 
luminescence signal representing cell viability (ATP content) was measured using a 
luminometer. The best results were obtained at 72 hours after transfection (Figure 19). In this 
experiment, lower light unit signal meant less ATP content and less viability. Upon 
optimization of the set up, si-Birc5 was selected as the proper positive and si-GFP as the 
negative control, and 50% reduction in cell viability (compared to negative control value) was 
used as a threshold for selection of candidates in screening procedures. 
 
 
Figure 19- Cell viability assay for control optimization. SiRNAs pools against Birc4, 5 and 
7 were transfected to MCF7 cells as positive controls, and “Allstars negative control” siRNA, 
firefly luciferase and GFP siRNA were used as negative controls. Cell viability was measured 
using CTGlo assay about 72h after transfection.cell viability is shown as related light unit 
(RLU). Error bars represent the SD based on five independent experiments. 
 
III.2.3 SiRNA screen to identify genes involved in survival of breast cancer 
cells 
One major application of RNAi is loss-of-function screens to identify and characterize genes 
of interest based on changes in the observed phenotype. In this study, a set of 107 siRNAs 
(pools of four siRNAs each targeting a single mRNA) were transfected into MCF7 cells and 
cell viability (as a phenotype read-out) was measured using an ATP-dependent luminescent 
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cell viability assay 72h after transfection. The relevant targets of those siRNAs that decreased 
the level of viability by at least 50% compared to the negative control (si-GFP) were defined 
as candidate genes contributing to cell survival (Figure 20). 
Three biological replicates of each siRNA knock-down were performed and positive „hits‟ 
were selected according to the criteria defined based on reaching the threshold value and 
reproducibility of the read-out in different replicates. Following these criteria, functional 
screening of 107 siRNAs resulted in the identification of PPP1R15B as a candidate gene with 
an profound impact on cell viability. This gene was selected for further validation experiments. 
Moreover, to avoid missing additional candidates that showed a 20-50% reduction in the cell 
viability read-out in this set of siRNA screen, eight genes including (PPP1R15B, EPHA3, 
PCTK2, HHLA2, TBC1D13, TTC19, ZNF436, SYTL4) were re-examined (Figure 20).  
 
 
Figure 20 - Loss-of-function screen identified PPP1R15B  as a candidate gene  involved 
in survival. Upon screening of 107 siRNAs, PPP1R15B (shown in red bar number 45) 
and 7 more genes (green bars, numbers: 48, 49, 78, 89, 90, 101) were selected for re-
analysis. MCF7 cells were transfected with individual siRNAs. 72h later, cell viability was 
measured by CTGlo assay. Dashed line shows the value of the negative control (siRNA 
targeting GFP, used for normalization). Error bars represent the standard deviation (SD) 
based on three experiments. 
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III.2.4 Accuracy of screening readout 
Knock-down and cell viability assays were performed for seven genes (EPHA3 [48], PCTK2 
[49], HHLA2 [78], TBC1D13 [89], TTC19 [90], ZNF436 [98], SYTL4 [101]) in addition to 
PPP1R15B [45]. By replicate analysis of all eight genes, hit value (50% reduction of cell 
viability compared to negative control si-GFP value) for cell viability was observed 
specifically by silencing of the PPP1R15B (Figure 21). Therefore, PPP1R15B gene was 
selected as the only promising candidate for more detailed validation and functional assays. 
 
 
Figure 21- Cell viability assay for candidate genes. Cell viability assay shows the change 
for ATP levels produced by cells after silencing of the candidate genes PPP1R15B, EPHA3, 
PCTK2, HHLA2, TBC1D13, TTC19, ZNF436 and SYTL4 compared to the negative control 
siGFP (red bar). Error bars represent the standard deviation (SD) based on three 
experiments. 
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III.2.5 Validation of the cell death inhibitory function for candidate gene 
PPP1R15B 
To test the specificity of the cell death inhibitory phenotype observed by the cell viability 
assay for PPP1R15B, further validation and characterization experiments were carried out 
including: i. knock-down using different single siRNAs and measuring RNA expression level 
and cell viability, ii. measuring the PPP1R15B protein level to evaluate knock down 
efficiency and iii. validation of  an apoptosis phenotype readout using FACS analysis and PI 
staining. 
III.2.5.1 Efficacy of the PPP1R15B silencing phenotype 
Four single siRNAs targeting different sequences of the PPP1R15 gene were tested for knock-
down efficacy and specify of the cell viability phenotype readout. To determine the efficacy 
of siRNAs with respect to their target genes, degradation of targeted mRNA after the 
application of siRNA needed to be tested. The RNA expression levels were evaluated by 
quantitative real time PCR. MCF7 cells were transfected with different siRNAs against 
PPP1R15B mRNA (si-ppp 1,2,3 and 4) and 48h after transfection, the target mRNA level was 
measured by qRT-PCR. 
Two siRNAs of four showed a similar efficacy, reaching a maximum knock-down of 
PPP1R15B RNA compared to si-GFP non-silencing control in this experiment. Lamin B and 
PGK were used for the normalization of expression data (Figure 22A). 
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Figure 22- The silencing efficacy of four si-PPP1R15B (si-ppp) monitored by qRT-PCR 
and cell viability assay. (A) Expression of PPP1R15B was measured by qRT-PCR in MCF7 
cells transfected by different siRNAs targeting its mRNA. Transfection of si-ppp sequence 2 
and 4 (blue) resulted in a profound reduction of PPP1R15B RNA level compared to a non-
targeting siRNA (pink bar si-GFP). (B) Measurement of cell viability at 72h after transfection 
with siRNAs-PPP (1-4), si-Birc5 (red bar) as positive control and si-GFP (green bar) as 
negative control. 
 
To evaluate the correlation of knock down efficiency with phenotype readout, cell viability 
was tested 72 hours after the transfection of MCF7 cells using all four single siRNAs 
targeting PPP1R15B, si-Birc5 as positive and si-GFP as negative controls (Figure 22B). 
In this experiment, cell viability was reduced to less than 50% when compared to the negative 
control (si-GFP) after transfection of cells with si-PPP(2) and si-PPP(4) and si-Birc5 (positive 
control). The observed phenotype following silencing of PPP1R15B was strongly correlated 
with the profound knock-down mediated by the two siRNAs shown in Figure 22A. 
III.2.5.2 The impact of  PPP1R15B  knock-down at the protein level 
The specific knock-down of PPP1R15B RNA is expected to show a corresponding effect at 
the protein level. To investigate the knock-down efficiency of si-ppp(2) at the protein level, 
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MCF-7 cells were transfected with the siRNA at a concentration of 50nM. After 48h, the cells 
were lysed and PPP1R15B protein levels were assayed by Western blot using a PPP1R15B-
specific monoclonal antibody. As a negative control, cells were also transfected with siRNA 
directed against GFP at a final concentration of 50nM in parallel. The housekeeping protein 
GAPDH was used as a loading control. The same amount of proteins for si-PPP and si-GFP 
transfected cells, were loaded onto gel. Transfection with si-PPP caused reduction in the 
PPP1R15B protein level when compared to si-GFP negative control. As it is shown in Figure 
23, the amount of the control protein was also slightly reduced by PPP1R15B deficiency. This 
might be due to the role of PPP1R15B in global protein biosynthesis (IV.2.5). Evaluating 
protein levels of other housekeeping genes in this experiment may help to verify this effect. 
 
Figure 23- Western blot analysis of PPP1R15B protein expression. siRNAs were 
transfected into MCF-7 cells. After 48 h, cells were lysed and protein expression was 
analyzed by western blot. GAPDH and PPP1R15B were detected with specific antibodies. 
Protein analysis 48 h after transfection showed reduction of PPP1R15B levels in si-PPP2-
transfected MCF-7 cells.  
 
III.2.5.3 Apoptosis induction upon PPP1R15B knock-down cells 
An apoptosis assay was applied to determine the consequences of PPP1R15B knock-down in 
MCF7 cells (Figure 24). After transfection with different siRNAs against PPP1R15B, the 
transfected cells were stained with propidium iodide and analyzed by flow cytometry. Our 
results demonstrated that an increase of apoptotic cell number can be achieved in the presence 
of efficient PPP1R15B siRNA knock-down compared to negative control experiments. Based 
on reduced DNA content compared to the normal G1 population, sub-G1 cells were 
considered as apoptotic cells. The siRNAs targeting PPP1R15B, Birc5 (positive control) and 
GFP (negative control) were transfected into MCF-7 cells at a concentration of 50nM. The 
percentage of subG1 cells was increased more than 4 fold by deficiency of PPP1R15B and 
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Birc5 when compared to si-GFP (Figure 24A). Thus, apoptosis was induced efficiently by 
silencing of PPP1R15B (si-PPP2, si-PPP4) and positive control Birc5 in MCF7 cells (Figure 
24 B). 
 
 
Figure 24- Apoptotic phenotype mediated by PPP1R15B silencing. (A) The percentage of 
apoptotic cells (sub-G1 cells) of a single experiment measured by FACS analysis is shown. 
Birc5 and GFP were positive and negative controls, respectively. (B) The fold change in 
apoptosis induction was confirmed by individual siRNAs transfection targeting different 
sequences of PPP1R15B as well as Birc5 and GFP. Error bars represent the standard 
deviation (SD) based on three independent experiments. 
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III.2.6 Effect of PPP1R15B deficiency on caspase activation 
In order to confirm induction of apoptosis after silencing of PPP1R15B, MCF7 cells were 
transfected with siRNAs targeting Birc5, PPP1R15B or GFP and the activity of caspases-3/7, 
as key mediators of apoptosis, was measured by the caspase-Glo3/7 assay (Promega). 
Compared to the negative control (si-GFP), the activity of caspase-3/7 was considerably 
higher in Birc5-silenced cells (positive control, 6 fold) whereas it was slightly higher in 
PPP1R15B-silenced cells (2.2 fold by siPPP2) (Figure 25). 
 
Figure 25- Caspases-3/7 activation upon PPP1R15B silencing. MCF7 cells were 
transfected with siRNA targeting GFP (si-GFP as negative control), PPP1R15B (si-PPP 1-4) 
or Birc5 (si-Birc5 as positive control) and the activity of caspase-3/7 was determined by 
caspase-Glo 3/7 luminescent assay. The results are displayed as fold changes in caspase 
activity relative to si-GFP value. Error bars represent the standard deviation based on three 
experiments. 
 
 
III.2.7 Apparent involvement of PPP1R15B in cell cycle regulation 
We further analyzed functional properties of PPP1R15B by investigating cell cycle 
distribution patterns using FACS analysis following PPP1R15B silencing. As shown in Figure 
24, PPP1R15B knock-down by si-PPP(2) strongly induced apoptosis (40%) when compared 
to the negative control si-GFP. Moreover, the proportion of S-phase cells was found to be 
reduced in the PPP1R15B silenced cell population compared to the control cells (si-GFP 
transfected) 72 hours after transfection (Figure 26). The frequency of cells distributed in S and 
G2 phases are significantly reduced (p<0.0002, p<0.005 respectively) upon silencing of 
PPP1R15B in comparison to the control transfection (Table 4). Taken together, based on this 
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observation, the cell cycle was arrested in the G1 phase and progression of cell cycle toward 
phase S and G2 was inhibited by PPP1R15B deficiency. Subsequently arrested cells undergo 
apoptosis as revealed by their accumulation in subG1 (Figure 26). 
 
 
Figure 26- Cell cycle analysis of PPP1R15B knocked-down cells. Cell cycle distribution of 
a single experiment is shown. MCF7 cells were transfected by si-PPP targeting PPP1R15B 
and with si-GFP as negative control. Cell cycle distribution was analyzed 72h after 
transfection by PI staining and FACS analysis.  
 
 
 
 
Table 4- Cell cycle profile upon PPP1R15B and GFP (negative control) knock-down. 
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III.2.8 Inhibition of proliferation by PPP1R15B silencing 
One of the most accurate method to measure proliferation is to measure DNA synthesis 
directly. The effect of PPP1R15B deficiency on cell proliferation was examined using the 
ClickiT™ (an antibody-based detection of the nucleoside) and FACS assay. At 72h after 
transfection of MCF7 cells with siRNA targeting, PPP1R15B and si-GFP (negative control), 
cell proliferation was measured by FACS. In this assay, cell proliferation was considerably 
reduced (50%) by PPP1R15B deficiency (Figure 27). 
 
 
Figure 27- Cell proliferation assay following silencing of PPP1R15B. (A) Decrease in 
percentage of proliferating cells confirmed by individual siRNA transfection targeting 
PPP1R15B, as well as GFP (negative control). Error bars represent the standard deviation 
(SD) based on three independent experiments. B) Percentage of proliferating cells of a single 
experiment measured by FACS analysis is shown.                     
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III.2.9 PPP1R15B expression in different breast cancer cell lines 
In order to determine the expression level of PPP1R15B in different breast cell lines qRT-
PCR was performed to measure the RNA level in breast cancer cell lines. Available breast 
cancer cell lines MCF7, MDA-MB231, SKBR3, EVSAT, MDA-MB435, T47D and HDQP1 
were included in the measurements. Various levels of PPP1R15B RNA expression were 
observed in different cell lines by qRT-PCR. The highest values were obtained in MCF7, 
MDA-MD231, T47D cells. In contrast, SKBR3, MDA-MB435 and HDQP1 cell lines showed 
a low level of PPP1R15B expression (Figure 28). Therefore, highly PPP1R15B expressed cell 
lines, MDA-MB231, T47D and one of low expressing cell lines (SKBR3), were selected for 
further investigation of PPP1R15B deficiency on cell viability.  
 
Figure 28- Expression level of PPP1R15B in different breast cell lines monitored by 
qRT-PCR. mRNA expression level of PPP1R15B was measured in 6 breast cancer cell lines 
by qRT-PCR. Expression values were normalized to the expression levels of PGK and Lamin 
B housekeeping mRNAs. 
 
 
III.2.10 Investigation of PPP1R15B deficiency effect on cell viability in 
other breast cancer cell lines 
To investigate the contribution of PPP1R15B to the viability of other breast cancer cell lines, 
in addition to MCF7, cell lines including MDA-MB231, SKBR3 and T47D were examined. 
Knock-down efficiency of siRNA against PPP1R15B was tested by qRT PCR. The set up 
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using standard transfection (II.2.2.4) was efficient for MCF7, MDA-MB231 and SKBR3 
(Figure 29 A). Cell viability was measured 72h after transfection of the above-mentioned cell 
lines with siRNA targeting PPP1R15B and siRNA-GFP (negative control). Significant 
reduction of cell viability was obtained upon silencing of PPP1R15B only in MCF7 (45%) 
cells when compared to the negative control (Figure 29 B) (see section IV.2.6).  
 
 
Figure 29- Silencing efficacy and effect of si-PPP1R15B (si-ppp) monitored by qRT-PCR 
and cell viability assay. (A) Transfection of si-ppp led to PPP1R15B mRNA level reduction. 
(B) Cell viability was measured 72h after siRNA-PPP, si-GFP (negative control) transfection 
of MCF7, MDA-MB231 and SKBR3 breast cancer cell lines. 
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IV Discussion 
The completion of the human genome sequence followed by initial functional analyses of the 
human transcriptome has resulted in the identification of novel genes, most of them 
uncharacterized or with poorly understood functions (Birney et al., 2007). Currently, for 
functional analysis of candidate genes, recombinant DNA or RNA molecules are widely used 
to over-express or to knock-down specific target genes in model cell cultures. When followed 
by an appropriate read out of the phenotype, such gene modulation approaches can be applied 
to identify gene functions related to certain cellular pathways (Sturzl et al., 2008). The aim of 
this study was to exploit the potential of loss-of-function screening to identify novel genes 
which are involved in apoptosis and cell survival. To reach this goal, we applied a functional 
genomics approach using RNAi technology in two different cell line models. A normal cell 
line, human embryonic kidney cells (HEK293T), and the tumorigenic MCF7 cell line were 
used for RNAi transfection and functional read out assays. Screening in HEK293T cells was 
carried out using short hairpin-coding constructs (shRNA) targeting 288 poorly characterized 
human genes. By measuring apoptosis as a readout of loss-of-function screening, CHMP5 was 
identified as a candidate for detailed functional and pathway analysis. Further investigation 
revealed an involvement of CHMP5 in apoptotic cell death and provided evidence on 
involvement of TNFR1 surface expression as an upstream and NF-B signaling as a 
downstream affected factors. RNAi screening in breast cancer MCF7 cells using siRNAs 
targeting 107 selected genes over expressed in pNC identified PPP1R15B as a validated gene 
involved in survival and proliferation of MCF7 cells. 
IV.1 shRNA screening in non-tumor cells 
IV.1.1 An optimized method for screening of apoptotic phenotype mediated 
by loss-of-function experiments 
Ongoing research programs aim to increase the speed of gene function analysis in mammalian 
cells by i. miniaturization of assays, ii. automatization of experimental processes and iii. 
improvement and automatization of data recording and management. In order to reach this 
goal a large number of cell-based assays has been developed over decades of cell culture 
studies to determine gene function (Sturzl et al., 2008). In 2001, reversely transfected cell 
microarrays were introduced as an approach for parallel high throughput analysis of gene 
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function in mammalian cells (Ziauddin and Sabatini, 2001). This method has been applied in 
various screening settings, such as screening of phenotypes caused by gene silencing or over- 
expression upon reverse transfection of arrayed cDNA or siRNA molecules (Erfle et al., 2007; 
Sturzl et al., 2008). The approach has offered the possibility of assessing morphological 
changes, such as apoptotic body formation, at a high resolution. Previous studies have shown 
that the reverse transfection assay is a powerful tool to screen for pro-apoptotic genes 
(Mannherz et al., 2006). In this study, the reverse transfection array was applied to identify 
putative anti-apoptotic genes based on apoptotic body formation phenotype, detected by 
fluorescence microscopy as a read out for the screening. Fluorescence microscopy analysis of 
the tranfected cells 72 hours after reverse transfection showed no detectable significant 
phenotypic changes. As shown in Figure 8, apoptotic cells were detected just in a few shRNA 
transfected cell clusters (spots on the slide). However, even in positive clusters, the amounts 
of observed apoptotic cells were not high enough to distinguish the corresponding genes as 
apoptosis related candidates. Since a sensitive and reproducible detection method was not 
achieved by this reverse transfection array, the strategy of screening and read out assaywas 
therefore changed to a standard direct transfection and detection of cell death using a sensitive 
method. A rapid and simple method for measuring apoptosis can be achieved by propidium 
iodide staining of cells to stain DNA and flow cytometry analysis using FACS, which is able 
to determine the percentage of apoptotic nuclei or recognize the apoptotic cells in a 
heterogeneous cell population (Nicoletti et al., 1991). In the current work, we used FACS to 
facilitate the measurements of apoptosis mediated by 288 shRNAs in a 96-well assay format. 
PI staining coupled with FACS analysis was also used for further validation analysis and 
detection of apoptotic cells by single transfection of siRNAs or cDNA constructs. 
IV.1.2 Identification of candidate genes on the bases of shRNA screen  
The success of an RNAi screen can be assessed by the false-positive and false-negative rates. 
The false negative rates usually estimated by measuring the hit rate for known positive control 
and negative control genes in specific phenotype readout. Reproducibility between replicates 
in each series of assays can provide information on false positive rates (Boutros and Ahringer, 
2008). Insufficient silencing of genes might disturb the observable phenotype, and contribute 
to the false negative rate of the screen. The false positive rate of a primary screen can be 
estimated using the results of the secondary assays. Most, or all, of the positive hits identified 
in the primary screen after validation are likely to be „real‟. Secondary screens reveal which 
genes are of particular relevance (Boutros and Ahringer, 2008).  
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In this study, four candidates were initially selected upon screening. Of those, three were 
excluded; one (Opsin) due to incorrect sequence of the analyzed gene and two due to non-
reproducible results when repeating the experiments. Therefore, the rate of false positives in 
this study, was as high as one percent, which is a low rate. Such a success rate can be 
achieved in a well-designed and well-controlled screen. On the other hand, false negative 
results might be obtained due to problems regarding transfection efficiency and knock-down 
efficacy of each individual shRNA. In this screen, it was not possible to exclude loosing 
candidates due to a non-effective knock-down. In the present study, reproducible experiments 
showed fold change increases in apoptosis made by silencing of CHMP5, which was 
comparable to those made by positive controls, the well-known anti-apoptotic genes, Birc4, 
Birc5 and Birc7. Therefore, we selected CHMP5 as a proper candidate for further validation 
assays. 
IV.1.2.1 Validation of CHMP5  
Validation assays were performed to confirm the involvement of CHMP5 silencing in cell 
death. The possible risk for RNAi-induced off-target effects has recently been demonstrated. 
To exclude the possible off-target effects induced by shRNAs used in the first screen, we 
tested siRNAs targeting different sequences of CHMP5 mRNA. As it was shown in Figure 12, 
CHMP5 silencing using both siRNAs increased the level of apoptosis, however, this effect 
was stronger for one of the siRNAs. Therefore, we used this siRNA in further analyses. The 
apoptotic phenotype observed by siRNA silencing of CHMP5 suggests that the apoptotic 
phenotype mediated by sh-CHMP5 was not due to an off-target effect, but was rather a 
CHMP5-specific phenotype. Quantitative RT-PCR was also used as a sensitive tool to 
measure target mRNA levels to ensure the effective knock-down in each experiment. To 
further validate and characterize the CHMP5 anti-apoptotic function, we performed over-
expression assays by transfecting a human CHMP5 expression vector (pCMV6-CHMP5) into 
cells followed by the chemical induction of apoptosis using etoposide.  The expected result 
was a reduction of apoptosis induced via addition of etoposide by over-presention of an anti-
apoptotic gene. In this experiment, induction of apoptosis was compensated by over 
expression of Birc4 (positive control) and human CHMP5. Since CHMP5 is an evolutionary 
conserved gene, over-expression of the murine sequence also affected the percentage of cell 
death. This over-expression analysis showed that CHMP5 played a role in modulating 
chemically induced apoptosis and gave rise to the inverse CHMP5-phenotype compared to the 
CHMP5 loss-of function studies. This further emphasized an anti-apoptotic function for 
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CHMP5. Rescue experiments were also carried out successfully by co-transfection of human 
CHMP5 shRNA together with human or murine CHMP5 over-expression vectors, thereby 
rescuing the phenotypic effect of CHMP5 over-expression. This represents a stringent way to 
verify the selectivity and the specificity of the knock-down phenotype. 
IV.1.3 Further functional assays 
IV.1.3.1 Caspase activity and apoptotic pathway  
Common characteristics of most apoptotic processes are the activation of the caspase cascades. 
In general, activation of upstream caspase-9 is associated with mitochondria-mediated 
apoptosis (intrinsic pathway), whereas activation of caspase-8 frequently is mediated by death 
receptor-regulated apoptosis (extrinsic pathway). Activation of either pathway leads to 
activation of the downstream caspase-3/7. It has also been shown that the connection between 
these apoptotic pathways can be made by activated caspase-8, which triggers the intrinsic 
pathway, resulting in activation of caspase-9 and, thereafter, downstream caspases (Kaufmann 
and Hengartner, 2001; Donepudi and Grutter, 2002; Liu et al., 2005). Investigating CHMP5-
mediated caspase cascade activation, we measured active caspase-8, 9 and 3/7 following 
CHMP5 silencing. 
A challenge in caspase activity assays is to figure out the exact time point for correct 
measurement. The best time point can be identified by the differences between values of the 
negative and positive controls. In addition, an essential step to set up a caspase activity assay 
is utilization of proper positive controls for each particular assay. In  the apoptosis pathways, 
FLIP and Birc4 are known as effective inhibitors of caspase 8 and caspase 9 activity 
(Philchenkov, 2004). Activity of caspase 8 or 9 can be altered by silencing of the FLIP and 
Birc4, respectively. In order to identify affected key pathway (extrinsic or intrinsic) in the 
apoptosis mediated by CHMP5 silencing, activated caspase 8 and 9 levels were monitored 
following CHMP5 modulation. Of significance, caspase 8 and 9 are apical caspases in the 
apoptotic pathway and, as such, are activated at an earlier time point than caspase 3/7 
(terminator caspase in the pathway). In this study, the caspase activity following CHMP5 
silencing was measured at different time points, starting 8 hours after transfection and 
continuously thereafter every 4 hours. The best results were obtained between 16 to 24 hours 
after transfection for caspase 8, 9, and at 48h for caspase 3/7. Based on our data, CHMP5 
deficiency induces apoptosis by activation of caspase-3/7, mainly via caspase-8 extrinsic 
cascade activation. The slight activation of caspase-9 observed in this study might be a further 
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downstream consequence in the caspase cascade, due to cross-activation of the intrinsic 
pathway. 
IV.1.3.2 Expression array analysis: genes and pathways affected by CHMP5 
modulation 
IV.1.3.2.1 Apoptosis related genes and expression changes induced by CHMP5 silencing 
Considering the fact that apoptosis is controlled by many factors, and results from an 
imbalance between activity of genes that promote and genes that repress apoptosis, we 
conducted a microarray-based study to obtain comprehensive transcriptome patterns following 
CHMP5 modulation. Characterization of the regulatory effect of CHMP5 on transcriptome 
patterns indicated that a number of apoptosis-associated genes are dysregulated upon CHMP5 
silencing (see tables 1 and 2). Apoptosis-inducer genes included: 
 - ATF3 (activating transcription factor 3) which is known to induce apoptosis in cancer and 
enhances etoposide induced apoptosis in Hela cells, it promotes down regulation of anti-
apoptotic genes such as Bcl2 ,Bcl-XL and IAP families (Birc4 and Birc3) (Yan et al., 2005; 
Hua et al., 2006; Huang et al., 2008), 
- PPP1R15A (protein phosphates 1 regulatory subunit15A) that is involved in growth arrest 
and regulation of apoptosis (Ayllon et al., 2000; Grishin et al., 2001),  
- GADD45A (Growth arrest and DNA-damage-inducible alpha), which contributes to 
apoptosis via activation of JNK and/or p38 MAPK signaling pathways (Takekawa and Saito, 
1998). 
Known genes with anti-apoptotic functions included: 
- CHMP2A (Charged Multivesicular body Protein 2A, one of the CHMP family genes) (Wu et 
al., 2006),  
- APBB3 (FE65-like protein), a gene with an apoptosis inhibitory domain (Cao et al., 2000). 
- MSRB2 known as a gene with apoptotic inhibitory function (Kwak et al., 2009). 
According to the expression array analysis, CHMP5 indeed affects the activity of other genes 
involved in apoptosis, underlying its anti-apoptotic function via regulation of genes involved 
in apoptosis. 
IV.1.3.2.2 Pathways affected by CHMP5 modulation 
With the advent of microarrays, it was hoped that the knowledge of genome-wide expression 
levels will speed up the understanding of biological systems. The effect of induction and 
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repression of target genes on metabolic and regulatory pathways is important in human 
disease, particularly in cancer (Nakao et al., 1999). In the present study, the main goal of the 
genome-wide expression array analysis was to identify the impact of CHMP5 expression on 
other signaling pathways. Expression data were analysed using commercial ingenuity 
pathway analysis and a homemade comprehensive gene pathway analysis software (Engel et 
al, in preparation). Comprehensive gene pathway analysis software helps to identify  
pathways, which are potentially involved in human disease, particularly in cancer. Analysis of 
array data by comprehensive gene pathway analysis revealed that several pathways involved 
in different cancer types such as AML, prostate, thyroid, endometrial cancer were regulated 
upon CHMP5 modulation. Further pathways involved in metabolism and degradation of cell 
products were also affected. 
Recent evidence indicates that disrupting the mouse CHMP5 gene by homologous 
recombination results in a phenotype of early embryonic lethality, reflecting defective late 
endosomal function and dysregulation of multiple signaling pathways like NF-κB and TGFβ 
(transforming growth factor β). Dysregulation of TGFβ signaling is attributed to the lack of 
degradation of internalized receptors (Horii et al., 2006; Shim et al., 2006). More detailed 
analysis using Ingenuity allowed us to identify genes implicated in the NF-κB network. Most 
of those genes were apoptosis-related genes and were up-regulated upon CHMP5 deficiency. 
Functional study on NF-κB activity using a reporter assay confirmed that NF-κB activity is 
influenced by CHMP5 modulation. Thereby, apoptosis signaling triggered by CHMP5 
deficiency can be mediated by the alteration of NF-κB activity. In this study, apoptosis was 
observed as consequence of CHMP5 silencing. In addition, investigation of caspase cascade 
activation showed the impact of CHMP5 deficiency on activation of caspase 8 induced 
apoptosis and the involvement of the extrinsic apoptosis pathway. On the other hand, pathway 
analysis and reporter assays confirmed that NF-κB activity is altered by CHMP5 silencing and 
over-expression. Previous studies showed that activation of membrane cell death receptors, 
like TNFR1, leads to activation of the caspase-8 cascade and the NF-κB pathway (Kaufmann 
and Hengartner, 2001; Micheau and Tschopp, 2003; Dutta et al., 2006). Interestingly, 
investigation of upstream molecular mechanisms leading to apoptosis induction by CHMP5 
revealed significant changes in cellular surface expression of TNFR1 following CHMP5 
modulation. In addition, expression array and IPA analysis revealed regulation of TNFR1-
induced apoptotic genes such as PEA-15 (Condorelli et al., 1999). These observations suggest 
that TNFR1 could act as an effector to mediate apoptosis induction by CHMP5 deficiency, 
resulting in activation of the caspase 8 cascade and the extrinsic apoptotic pathway. 
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IV.1.4 Charged multivesicular body protein 5 (CHMP5); One gene, multiple 
functions 
As a result of this screen, CHMP5 was identified as a gene with an impact on apoptosis. All 
further experiments testing for specificity of the CHMP5 knock-down phenotype, CHMP5 
over expression and rescue assays as well as specific caspase-inhibitor experiments and 
expression array analysis, confirmed an involvement in the apoptotic pathway. 
CHMP5 gene is located on chromosome 9 (9p13.3). The CHMP5 gene product is described as 
a member of the CHMP-family of coiled-coiled protein homologous to the yeast 
Vps60/MOS10 gene, and has been shown to be a component of the endosomal sorting 
complex required for the transport III (ESCRT-III) complex. ESCRT-III is involved in 
degradation of surface receptor proteins and in formation of endocytic multivesicular bodies 
(MVBs). It plays an important role in the modulation of various signaling pathways (Shim et 
al., 2006; Hurley and Ren, 2009; Saksena and Emr, 2009; Wollert et al., 2009). However, in 
addition to MVB formation, other functions like apoptosis modulation have been discussed 
for the members of the ESCRT-III complex (Wu et al., 2006).  
Interestingly, characterization of the regulatory effect of CHMP5 on signaling pathways in the 
current study showed that PPAR, Notch and mTOR signaling were effectively dysregulated 
upon CHMP5 modulation. In addition, many NF-κB associated factors influencing apoptosis 
were dysregulated upon silencing of CHMP5. Likewise, the functional experiments in our 
study showed significant changes in cell surface expression of TNFR1 and in NF-κB activity 
in CHMP5 modulated cells. It is known that TNFR1 triggers distinct signaling pathways, 
leading to both to the activation of NF-κB transcription factors, as well as the induction of 
apoptosis (Micheau and Tschopp, 2003; Dutta et al., 2006). In addition to the well known 
functions of NF-κB, it was recently shown that, in a certain context, NF-κB activation may 
result in the expression of pro-apoptotic genes inducing apoptotic pathways (He and Ting, 
2002; Siebenlist et al., 2005; Thyss et al., 2005). Moreover, several interaction partners of 
CHMP5 in the ESCRTIII complex, like CHMP2A, B, CHMP4A and CHMP6 (Tsang et al., 
2006) have also been shown to be regulated by CHMP5 modulation. All these findings 
suggest that the effect of CHMP5 on apoptosis is mediated via possible changes in the 
ESCRTIII complex, thereafter resulting in the regulation of different pathways such as NF-
κB-signaling.  
CHMP5 is a unique CHMP family protein that does not belong to any other subfamily of 
CHMP proteins. It may probably play roles beyond those described for the endocytic pathway. 
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The 5' end of the CHMP5 gene is separated by only 414 base pare (bp) from the opposing 
strand of the Bag1 gene (Takayama and Reed, 2001), suggesting that both genes may be co-
regulated at the transcriptional level. Bag1 is clearly involved in the modulation of apoptosis, 
cell proliferation, transcription and cell motility as a multifunctional regulator. This could 
imply that CHMP5 might participate in functions modulated by Bag1. 
IV.2 RNAi screen in the breast cancer cells 
IV.2.1  Expression profiling  revealed candidate genes for functional study 
In a recent study, expression profiling of breast cancer patients with complete response and 
non-response was performed to identify gene expression signatures predicting pathologic 
complete response to gemcitabine, epirubicin, and docetaxel treatment in primary breast 
cancer (Thuerigen et al., 2006). In the current work, the expression data obtained from that 
study was considered to identify genes over-expressed in pNC when compared to the pCR 
group. Significant analysis of microarrays identified 115 genes that were significantly up 
regulated in pNC group. Based on available siRNAs, 107 of these genes were selected as 
candidate genes for functional screening for their impact on cell survival. A candidate gene, 
which could be identified in such a screening, may prove to underlie the resistance to therapy 
or in general acting as a pro survival gene over-expressed in tumor cells. 
IV.2.2  siRNA screen and identification of genes involved in cell survival  
The major aim of this study was to identify a target gene, whose siRNA-induced knock-down 
would efficiently trigger cell death. In order to perform a successful screen using siRNAs, 
efficient delivery of highly functional and specific siRNA molecules into appropriate cells is 
required. Upon examination of different transfection reagent and approaches, siPORT™ 
NeoFX™ was selected for reverse transfection of MCF7 cells in a 96 well format. Using this 
method, the extent of cell death was comparable among different transfection experiments, 
and positive and negative controls provided the thresholds that allowed us to determine, 
whether a siRNA can be considered as a positive, negative or neutral effector in the assay.  
Several studies showed that the smaller transfected constructs provide better transfection 
efficiency. SiRNAs with 20-21 nucleotides in length are more easily to transfect than larger 
expression plasmids coding for shRNAs. Therefore, we used siRNAs (pool sequences) for the 
screening approach. By using pools of four siRNAs targeting one single gene, we reduced the 
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costs of screening, but this event might have also increased the chance for off-target effects of 
a single siRNA on an observed phenotype (Elbashir et al., 2001b). This can be overcome by 
retesting single siRNAs separately. In order to estimate the hit rate and to minimize the false 
negative rate, three anti-apoptotic genes were selected as positive controls. Reproducible 
results from replicate wells provided information about the value of the readout for this 
screening. The three independent positive controls (Birc4, Birc5 and Birc7) used in this screen 
covered both weak and strong hits, which allowed the detection of weak and strong candidate 
genes. Weak signals could be caused either by partial knock-down of a gene, which 
potentially has a strong effect, or a strong knock-down of a gene potentially having a weak 
effect (Boutros and Ahringer, 2008). A number of negative controls including all-stars 
negative control, siRNAs targeting firefly luciferase or GFP tested in this study were used to 
evaluate off-target effects. A reproducible decrease in cell viability achieved by knock-down 
of Birc5, provided a strong upper threshold for selecting candidates. In addition, to consider 
the partial knock-down event, siRNAs showing a lower threshold (Birc4, and-7, each one 
representing a weak positive control) were additionally re-tested in the validation experiments. 
Birc5 deficiency effectively reduced the cell viability of MCF7 cells, therefore we used si-
Birc5 as a proper positive control for further analysis. All negative controls were used for 
initial screening. We selected one of them, si-GFP, to be used as negative control in additional 
assays. Since the gene knock-down efficiency was not tested in the RNAi screen, siRNAs 
causing reduction in cell viability were further analyzed in the validation assay. Therefore, 
eight candidates were selected for retesting in single assays and of those, only one 
(PPP1R15B), which was positive in the screen. 
IV.2.3 Validation of the candidate gene PPP1R15B 
Validation experiments are important for identifying the genes that are particularly relevant to 
the phenotype of interest (Moffat et al., 2006; Boutros and Ahringer, 2008). In this study, 
validation of a single candidate gene was performed by separately transfecting up to four 
single siRNA sequences into MCF7 cells. Validation of a candidate gene was scored positive, 
if at least two out of four siRNA sequences reduced cell viability to a similar degree as the 
pooled siRNAs targeting the candidate. Recent publications discussed that two or more 
siRNA sequences that knock-down the target gene and elicit the same phenotype, are  
sufficient to proof target specificity (Boutros and Ahringer, 2008).  In the current study, two 
of four single siRNAs targeting PPP1R15B led to reduction of cell viability comparable to the 
pooled siRNAs in the screening. The results from the cell viability reduction were in 
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concordance with knock-down efficiency measured by qRT-PCR. In addition, knock-down 
efficiency of the most effective single siRNA targeting PPP1R15B was also examined at the 
protein level by western blot analysis. A strong western blot signal is limited by the short half-
life of the PPP1R15B protein (about 45min) (Jousse et al., 2003). However, following this 
straightforward approach, PPP1R15B was identified as a potential validated candidate with a 
high capacity to reduce cell viability in MCF7 cells after knock-down by using additional 
functional assays. 
IV.2.4 PPP1R15B deficiency reduced cell proliferation and induced 
apoptosis in breast cancer cell line 
The balance between proliferation and apoptosis is crucial in determining the overall growth 
or regression of the tumor in response to chemotherapy. In the current work, we identified 
PPP1R15B as a gene involved in the viability of MCF7 cells. Reduction of cell viability could 
be a consequence of a stop in cell proliferation and/or increase in cell death. Therefore, we 
examined cell proliferation by FACS-based method. As it was shown in 27, cell proliferation 
is reduced about 50% by PPP1R15B deficiency. An apoptosis assay was performed to 
determine the effect of the PPP1R15B knock-down in MCF7 cells. Considering the sub-G1 
population as apoptotic cells, PPP1R15B deficiency increased apoptosis more than four fold 
over the negative control. 
Activation of caspase 3/7 following PPP1R15B silencing was not increased as strongly as the 
Birc5 knock-down. This might be due to inappropriate time point for measuring caspase 
activity for the PPP115B knock-down experiment or may indicate that this gene exerts its 
anti-apoptosis property through other cellular process (like cell proliferation) rather than direct 
control of apoptosis. Silencing of PPP1R15B could impair the cell proliferation process 
leading to cell death as a secondary effect or PPP1R15B deficiency does not lead to activate 
caspase3/7 properly. Reduction of cell proliferation on one hand and induction of apoptosis on 
the other hand by PPP1R15B silencing in MCF7 breast cancer cells, provided supporting 
evidence on contribution of this gene to breast cancer.  
Cell cycle analysis of the siRNA-PPP1R15B knock-down and control siRNA-GFP revealed 
significant differences. In the present study, FACS analysis of the stained DNA using 
propidium iodide showed an arrest in G1 phase of cell cycle distribution by PPP1R15B 
deficiency. Based on the results obtained from the cell cycle analysis, reduction of 
proliferative cells could be a consequence of cell cycle arrest following PPP1R15B deficiency.  
The current study suggests the involvement of PPP1R15B in cell cycle progression and 
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survival of breast cancer cell line MCF7. 
An interesting issue regarding the PPP1R15B is the consequence of knock-down in other 
breast cancer cells. The phenotypic effect of PPP1R15B silencing may be better detected in 
cells with higher endogenous expression. Therefore, cell lines such as MDA-MB231 and 
T47D with expression levels comparable to MCF7 were selected for PPP1R15B knock-down 
and cell viability assay. Among these cell lines, successful transfection of gene siRNAs was 
achieved for MCF7 and MDA-MB231. Of those cell lines, only MCF7 showed around 45% 
reduction in cell viability upon silencing of PPP1R15B. In addition, one of the low 
PPP1R15B expressing cells, SKBR3, was also tested for silencing effect of PPP1R15B.  
Interestingly, despite successful silencing, deficiency of PPP1R15B did not affect the cell 
viability of MDA-MB231 and SKBR3 cells. Since breast cancer is a heterogeneous disorder, 
observed variations in effect of PPP1R15B deficiency on cell viability in different breast 
cancer cell lines might be due to the different molecular properties of these cells. One major 
difference between these cells is the exclusive over-presence of estrogen receptor (ER) and 
progesterone receptor (PR) in MCF7 cells (Sotiriou et al., 2003; Neve et al., 2006). ER refers 
to a group of receptors that are activated by estrogen hormones (Dahlman-Wright et al., 2006). 
The main function of the ER is to regulate gene expression, as a DNA binding transcription 
factor (Dahlman-Wright et al., 2006). However, the ER has additional functions independent 
of DNA binding (Levin, 2005). The progesterone receptor also known as NR3C3 (nuclear 
receptor subfamily 3, group C, member 3), is an intracellular steroid receptor that specifically 
binds to progesterone hormone (Gadkar-Sable et al., 2005). ER and PR both have an effect on 
cell proliferation through activating the transcription of genes involved in cell growth and 
proliferation (Lange, 2008). Over presentation of ER or PR (“ER positive” and “PR positive”) 
in different types of breast cancer cell lines has previously reported (Neve et al., 2006). 
Of those cell lines tested in this study, MCF7 and T47D are ER positive/PR positive; MDA-
MB231 and SKBR3 are described as ER negative/PR negative cell lines (Neve et al., 2006). 
Considering these molecular differences and our observation that silencing of PPP1R15B 
resulted in decreased viability only in MCF7 cells, it is likely that PPP1R15B deficiency 
exerts its effect on cell viability via specific pathways that are regulated by hormone receptors 
such as estrogen and progesterone receptors.        
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IV.2.5 PPP1R15B, an interesting target for chemotherapeutic studies 
Protein phosphatase 1 regulatory (inhibitor) subunit 15B (PPP1R15B) is located on 
chromosome 1q32.1. Previous studies showed that PPP1R15B has the ability to associate with 
the catalytic phosphatase PPP1 subunit and to repress eIF2 phosphorylation when over-
expressed (Jousse et al., 2003; Harding et al., 2009). Eukaryotic translation initiation factor 2α 
(eIF2 α) phosphorylation inhibits protein translation initiation. Therefore, dephosphorylation 
of eIF2 leads to activation of the protein synthesis machinery. In knock-out PPP1R15B mice, 
arrest of embryos lacking PPP1R15B at the preimplantation stage was consistent with a role 
of the protein in eIF2 (αPI) dephosphorylation (Harding et al., 2009). In the current study, we 
identified the involvement of PPP1R15B in MCF7 cell proliferation and survival. These 
observations are in concordance with the ability of this gene to dephosphorylate eIF2, which 
is critical for cell viability.  
Expression array analysis of responding and non-responding breast cancer patients to 
chemotherapy revealed the PPP1R15B gene as an over-expressed gene in non- responding 
patients. Merging patients data and data produced from functional assays in cancer cell lines, 
suggests to further investigation of a possible role for PPP1R15B in resistance to 
chemotherapy. 
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VI. Supplementary data 
Table 5- Expression Arrest ™ shRNA library.  
Column A Column B Column C Column D 
Oligo ID Current Accession Release Plate Fold change in cell 
death 
v2HS_99386 NM_031284 2082 1,27 
v2HS_108899 XM_303656 2082 1,04 
v2HS_106350 XM_298971 2082 1,19 
v2HS_109826 XM_304205 2082 1,12 
v2HS_102054 XM_114087 2082 1,17 
v2HS_93615 NM_000546 2082 0,91 
v2HS_93536 NM_000533 2082 1,97 
v2HS_96705 NM_015485 2082 1,08 
v2HS_98358 NM_022755 2082 1,59 
v2HS_99751 NM_052897 2082 1,02 
v2HS_92212 M36341 2082 1,02 
v2HS_107692 XM_299635 2082 0,85 
v2HS_99682 NM_052875 2082 1,12 
v2HS_81744 NM_015229 2082 0,72 
v2HS_100819 XM_040866 2082 1,27 
v2HS_108244 XM_303544 2082 1,10 
v2HS_108043 XM_302939 2082 1,08 
v2HS_95675 NM_014848 2082 0,68 
v2HS_105509 XM_298808 2082 0,74 
v2HS_92458 NM_000339 2082 0,89 
v2HS_109992 XM_304234 2082 0,70 
v2HS_103048 XM_208555 2082 0,84 
v2HS_102694 XM_167168 2082 0,89 
v2HS_99423 NM_031290 2082 0,63 
v2HS_102635 XM_167134 2082 0,70 
v2HS_95765 NM_014867 2082 0,75 
v2HS_107848 XM_299667 2082 0,93 
v2HS_93983 NM_001050 2082 1 
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v2HS_110454 XM_304313 2082 0,77 
v2HS_93419 NM_000513 2082 2,63 
v2HS_107955 XM_302911 2082 0,54 
v2HS_97513 NM_016091 2082 0,57 
v2HS_100633 X64991 2082 0,76 
v2HS_96026 NM_014913 2082 0,61 
v2HS_93189 NM_000465 2082 0,66 
v2HS_101845 XM_093799 2082 0,72 
v2HS_98400 NM_022762 2082 0,87 
v2HS_105370 XM_292364 2082 0,49 
v2HS_100815 XM_040860 2082 0,77 
v2HS_106158 XM_298934 2082 0,70 
v2HS_109934 XM_304223 2082 1,18 
v2HS_95129 NM_006992 2082 1,07 
v2HS_91909 AF278761 2082 1,07 
v2HS_102558 XM_167044 2082 0,91 
v2HS_108982 XM_303669 2082 0,84 
v2HS_108635 XM_303610 2082 0,79 
v2HS_95112 NM_006989 2082 0,88 
v2HS_93697 NM_000565 2082 0,94 
v2HS_95204 NM_014755 2082 1,92 
v2HS_92868 NM_000409 2082 0,79 
v2HS_108611 XM_303606 2082 0,78 
v2HS_109733 XM_303799 2082 0,88 
v2HS_106179 XM_298937 2082 0,88 
v2HS_99525 NM_052842 2082 0,67 
v2HS_96984 NM_015571 2082 1,03 
v2HS_110197 XM_304270 2082 1,07 
v2HS_100355 NM_178531 2082 0,79 
v2HS_50067 NM_005120 2082 0,70 
v2HS_110808 XM_304375 2082 0,71 
v2HS_94144 NM_001085 2082 0,89 
v2HS_97570 NM_016101 2082 0,84 
v2HS_101802 XM_087245 2082 0,66 
v2HS_107407 XM_299577 2082 0,55 
v2HS_102025 XM_114057 2082 1,39 
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v2HS_91785 AF065858 2082 0,70 
v2HS_95024 NM_006963 2082 0,53 
v2HS_107440 XM_299583 2082 0,68 
v2HS_94640 NM_001178 2082 0,97 
v2HS_95167 NM_006999 2082 0,75 
v2HS_108711 XM_303624 2082 0,75 
v2HS_105242 XM_292336 2082 0,65 
v2HS_99735 NM_052888 2082 0,71 
v2HS_117956 NM_032143 2082 0,83 
v2HS_97583 NM_016103 2082 0,75 
v2HS_100161 NM_177979 2082 0,75 
v2HS_110113 XM_304256 2082 0,70 
v2HS_110270 XM_304282 2082 0,87 
v2HS_126426 XM_303961 2082 1,06 
v2HS_97249 NM_016039 2082 1,92 
v2HS_95179 NM_014751 2082 1,05 
v2HS_101450 XM_085974 2082 1,10 
v2HS_105530 XM_298811 2082 1,14 
v2HS_110899 XM_304392 2082 0,89 
v2HS_92324 NM_000315 2082 1,78 
v2HS_100667 XM_027054 2082 0,76 
v2HS_109597 XM_303776 2082 0,64 
v2HS_99318 NM_031273 2082 0,83 
v2HS_110719 XM_304358 2082 0,76 
v2HS_101990 XM_114028 2082 0,68 
v2HS_104670 XM_291735 2082 0,60 
v2HS_108399 XM_303571 2082 0,75 
v2HS_97310 NM_016050 2082 0,8 
v2HS_101013 XM_062958 2082 0,72 
v2HS_110467 XM_304315 2082 0,57 
v2HS_97528 NM_016094 2082 0,84 
v2HS_108139 XM_302970 2082 1,92 
v2HS_128761 XM_305060 2052 0,73 
v2HS_111583 NM_000590 2052 0,66 
v2HS_129996 XM_305270 2052 0,72 
v2HS_122689 XM_291991 2052 1,08 
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v2HS_126883 XM_304437 2052 0,62 
v2HS_118105 BC044246 2052 0,66 
v2HS_125581 XM_303817 2052 0,81 
v2HS_123108 XM_292566 2052 0,92 
v2HS_116405 NM_024096 2052 1,75 
v2HS_118242 NM_052948 2052 1,17 
v2HS_130113 XM_305290 2052 1,74 
v2HS_122936 XM_292500 2052 1,61 
v2HS_122468 XM_291898 2052 1,93 
v2HS_129041 XM_305109 2052 1,25 
v2HS_114320 NM_009171 2052 1,57 
v2HS_112211 Z34811 2052 1,5 
v2HS_121965 XM_210044 2052 1,43 
v2HS_118049 NM_032167 2052 1,35 
v2HS_110975 NM_015052 2052 1,78 
v2HS_118743 NM_178838 2052 1 
v2HS_126466 XM_303967 2052 0,96 
v2HS_122423 XM_291886 2052 1,03 
v2HS_120958 XM_167317 2052 1,37 
v2HS_123173 XM_292594 2052 1,07 
v2HS_129828 XM_305242 2052 1,08 
v2HS_130080 XM_305284 2052 2 
v2HS_115280 AK082587 2052 1,16 
v2HS_128067 XM_304640 2052 0,94 
v2HS_129692 XM_305220 2052 0,92 
v2HS_124791 XM_299758 2052 1,29 
v2HS_117818 NM_032119 2052 0,77 
v2HS_129789 XM_305236 2052 1,31 
v2HS_112775 NM_001237 2052 1,23 
v2HS_121954 XM_210027 2052 1,01 
v2HS_127399 XM_304524 2052 1,36 
v2HS_122326 XM_370662 2052 1,07 
v2HS_122903 XM_292488 2052 0,98 
v2HS_112317 NM_001006628 2052 1,92 
v2HS_125901 XM_303870 2052 1,44 
v2HS_112682 NM_001219 2052 1,27 
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v2HS_119731 XM_086791 2052 0,70 
v2HS_121188 XM_174639 2052 0,69 
v2HS_120464 XM_115026 2052 0,89 
v2HS_120416 NM_002154 2052 0,83 
v2HS_113461 NM_001365 2052 0,76 
v2HS_117194 NM_031418 2052 0,92 
v2HS_125239 XM_299852 2052 1 
v2HS_128718 XM_305053 2052 1,12 
v2HS_128323 XM_304683 2052 1,28 
v2HS_111231 AF527534 2052 1,31 
v2HS_119467 XM_065172 2052 1,78 
v2HS_113420 BC035974 2052 1,18 
v2HS_125723 XM_303841 2052 1,34 
v2HS_115032 NM_203379 2052 1,21 
v2HS_126958 XM_304450 2052 1,26 
v2HS_114178 NM_002073 2052 1,31 
v2HS_118113 NM_052918 2052 1,51 
v2HS_125448 XM_299892 2052 1,62 
v2HS_124685 XM_299737 2052 1,70 
v2HS_112699 NM_001223 2052 1,21 
v2HS_125791 XM_303852 2052 1,25 
v2HS_114451 NM_015641 2052 1,02 
v2HS_128707 XM_305051 2052 1,44 
v2HS_125400 XM_299882 2052 1 
v2HS_118023 NM_032160 2052 1,11 
v2HS_119805 BX648094 2052 1,15 
v2HS_112649 U88965 2052 1,23 
v2HS_129103 XM_305119 2052 1,18 
v2HS_111256 AJ276510 2052 1,23 
v2HS_122375 NM_001002925 2052 1 
v2HS_127678 XM_304571 2052 1,72 
v2HS_115755 NM_016410 2052 2,63 
v2HS_125023 XM_299802 2052 1,21 
v2HS_120996 XM_167360 2052 0,94 
v2HS_114602 NM_015681 2052 1,07 
v2HS_119659 XM_086666 2052 1,78 
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v2HS_121275 XM_370839 2052 1,10 
v2HS_128423 XM_305003 2052 1,02 
v2HS_125280 XM_299861 2052 1,47 
v2HS_118363 NM_052972 2052 1,31 
v2HS_121120 XM_168122 2052 1,03 
v2HS_118180 NM_052938 2052 0,83 
v2HS_119967 XM_088114 2052 1,01 
v2HS_118548 NM_172251 2052 1,13 
v2HS_126142 XM_303911 2052 0,87 
v2HS_112549 NM_000793 2052 0,78 
v2HS_115696 NM_016395 2052 0,75 
v2HS_112786 NM_001239 2052 0,75 
v2HS_116030 NM_016482 2052 0,8 
v2HS_126390 XM_303955 2052 0,72 
v2HS_129466 XM_305180 2052 1,04 
v2HS_113750 NM_001430 2052 2,07 
v2HS_116053 NM_016486 2052 0,89 
v2HS_116865 NM_030791 2052 0,86 
v2HS_115813 NM_016436 2052 0,90 
v2HS_120275 NM_199282 2052 0,98 
v2HS_124509 XM_299704 2050 1,45 
v2HS_128475 XM_305012 2050 0,92 
v2HS_118580 AK098243 2050 1,16 
v2HS_127050 XM_304465 2050 1,27 
v2HS_116165 AK022973 2050 0,87 
v2HS_111723 NM_000617 2050 1,05 
v2HS_114504 NM_015653 2050 0,91 
v2HS_111088 BC013143 2050 1,44 
v2HS_115378 NM_016311 2050 1,14 
v2HS_115382 NM_016312 2050 1 
v2HS_128033 XM_304634 2050 1 
v2HS_122367 XM_291857 2050 1,31 
v2HS_122129 NM_001004760 2050 1,67 
v2HS_114552 NM_015668 2050 1,12 
v2HS_118457 NM_148676 2050 1,66 
v2HS_122909 XM_292489 2050 1,53 
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v2HS_115009 AF169802 2050 1,08 
v2HS_111447 K01241 2050 1,31 
v2HS_126828 XM_304428 2050 1,15 
v2HS_116976 NM_030811 2050 1,36 
v2HS_115237 NM_016279 2050 1,34 
v2HS_119556 NM_024789 2050 1,37 
v2HS_119045 AB040926 2050 1,51 
v2HS_127432 XM_304530 2050 1,37 
v2HS_114427 NM_015634 2050 1,60 
v2HS_116953 NM_023668 2050 1,20 
v2HS_123529 XM_293001 2050 1,31 
v2HS_127318 XM_304510 2050 1,41 
v2HS_119242 NM_052892 2050 1,18 
v2HS_125203 XM_299837 2050 1,29 
v2HS_126354 XM_303949 2050 1,27 
v2HS_125335 XM_299871 2050 1,24 
v2HS_126875 XM_304436 2050 1,24 
v2HS_127377 XM_304519 2050 1,05 
v2HS_120350 AB037792 2050 1,10 
v2HS_123622 AK049977 2050 1,13 
v2HS_112799 NM_058241 2050 1,43 
v2HS_129658 XM_305214 2050 1,06 
v2HS_120046 XM_094565 2050 1,03 
v2HS_124163 XM_293204 2050 1,10 
v2HS_126951 XM_304448 2050 0,99 
v2HS_111995 NM_000682 2050 0,91 
v2HS_118009 NM_027654 2050 1,03 
v2HS_124122 XM_293182 2050 1,29 
v2HS_122024 XM_210107 2050 2,31 
v2HS_114339 NM_015602 2050 1,85 
v2HS_117152 NM_002138 2050 1,64 
v2HS_122701 XM_291994 2050 1,12 
v2HS_115983 NM_016472 2050 1,11 
v2HS_115853 NM_016445 2050 0,78 
v2HS_116025 NM_016481 2050 0,90 
v2HS_127044 XM_304464 2050 0,98 
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v2HS_120227 NM_008393 2050 0,77 
v2HS_122178 XM_210195 2050 1,01 
v2HS_122475 XM_291899 2050 0,97 
v2HS_116270 NM_022895 2050 0,86 
v2HS_115029 NM_016233 2050 0,85 
v2HS_129600 XM_305203 2050 0,97 
v2HS_124612 XM_299723 2050 0,92 
v2HS_118381 NM_052997 2050 0,78 
v2HS_116669 NM_030752 2050 0,92 
v2HS_129743 XM_305228 2050 1,31 
v2HS_121369 XM_208853 2050 1,05 
v2HS_128874 XM_305079 2050 1,18 
v2HS_114438 BC013144 2050 0,92 
v2HS_120607 NM_001005198 2050 0,78 
v2HS_112158 NM_000710 2050 0,78 
v2HS_116118 NM_005678 2050 0,77 
v2HS_124174 XM_293205 2050 0,76 
v2HS_126743 XM_304414 2050 0,76 
v2HS_111793 J03171 2050 1,02 
v2HS_130166 XM_305299 2050 0,76 
v2HS_120737 NM_001004745 2050 1,03 
v2HS_121335 XM_208821 2050 1,91 
v2HS_112035 NM_000689 2050 1,11 
v2HS_118847 NR_000039 2050 0,89 
v2HS_112726 NM_033339 2050 0,88 
v2HS_113000 NM_001275 2050 1,23 
v2HS_115106 NM_016249 2050 0,74 
v2HS_128362 XM_304691 2050 1,25 
v2HS_116349 AK052018 2050 1,17 
v2HS_130073 XM_305283 2050 0,96 
v2HS_115416 NM_016322 2050 1,30 
v2HS_112218 AB086123 2050 1,02 
v2HS_118086 NM_017871 2050 0,94 
v2HS_113011 NM_001277 2050 1,89 
v2HS_126311 XM_303941 2050 1,38 
v2HS_127080 XM_304470 2050 1,21 
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v2HS_118618 NM_178812 2050 1,28 
v2HS_122948 XM_292504 2050 1,11 
v2HS_112634 NM_001211 2050 0,98 
v2HS_126432 XM_303962 2050 1,04 
v2HS_112186 NM_000715 2050 0,89 
v2HS_123963 XM_293131 2050 1,05 
v2HS_111636 NM_000599 2050 0,81 
v2HS_121684 AF255565 2050 1,12 
 
*Column A: specific Oligo IDs in the library. Column B: Respective gene accession numbers. 
Column C: Original plate number in Expression Arrest ™ shRNA library. Colum D: Fold 
changes in cell death measured by PI staining and FACS analysis (normalized to negative 
control sh-luciferase). 
 
 
Table 6- 107 siRNA from Qiagen human siRNA library.  
Column A Column B Column C 
QiagenID Current Accession Fold change in cell 
viability 
HsDGV3_44 NM_005763 1,13 
HsDGV3_28 NM_004827 1,21 
HsDGV3_81 NM_000020 1,09 
HsDGV3_44 NM_000689 1,02 
HsNMV1_90 NM_001154 1,17 
HsDGV3_28 NM_014629 0,97 
HsNMV1_210 NM_005738 1,16 
HsDGV3_12 NM_004318 
NM_032466 
NM_032468 
1,16 
HsNMV1_91 NM_001698 1,16 
HsDGV3_81 NM_001204 0,94 
HsDGV3_45 NM_000060 1,15 
HsNMV1_130 NM_014550 1,06 
HsDGV3_48 NM_001239 1,05 
HsNMV1_158 NM_030911 1,05 
HsDGV3_9 NM_003671 
NM_033331 
1,12 
HsNMV1_111 NM_003956 1,05 
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HsNMV1_92 NM_001280 1,13 
HsNMV1_111 NM_012129 1,21 
HsNMV1_106 NM_003277 1,04 
HsNMV1_116 NM_016138 1,02 
HsNMV1_117 NM_006371 0,91 
HsDGV3_79 NM_005730 0,97 
HsNMV1_217 NM_021800 1,06 
HsDGV3_8 NM_015291 1,10 
HsNMV1_93 NM_001374 1,13 
HsNMV1_124 NM_015296 1,00 
HsDGV3_48 NM_001964 0,98 
HsDGV3_82 NM_005233 
NM_182644 
0,89 
HsDGV3_48 NM_005239 0,90 
HsDGV3_12 NM_012161 
NM_033535 
1,03 
HsDGV3_26 NM_013231 1,01 
HsNMV1_122 NM_014947 1,05 
HsDGV3_52 NM_002015 1,15 
HsNMV1_121 NM_007285 1,02 
HsNMV1_149 NM_022087 0,94 
HsDGV3_24 NM_018841 0,99 
HsDGV3_2 NM_001004051 
NM_138437 
0,93 
HsDGV3_66 NM_001018102 
NM_015532 
1,08 
HsNMV1_122 NM_014282 1,06 
HsNMV1_120 NM_007072 0,93 
HsDGV3_15 NM_032549 0,98 
HsDGV3_78 NM_005539 0,90 
HsDGV3_79 NM_014937 
NM_198330 
NM_198331 
0,90 
HsDGV3_59 NM_003749 0,91 
HsDGV3_80 NM_032833 0,48 
HsDGV3_43 NM_015074 
NM_183416 
0,94 
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HsNMV1_91 NM_001206 0,78 
HsNMV1_108 NM_033631 0,73 
HsDGV3_38 NM_000081 
NM_001005736 
0,73 
HsDGV3_89 NM_012301 1,16 
HsDGV3_29 NM_000898 1,23 
HsDGV3_85 NM_003618 1,07 
HsDGV3_60 NM_002387 0,96 
HsDGV3_53 NM_004992 1,00 
HsDGV3_26 NM_002404 1,15 
HsNMV1_99 NM_005938 1,06 
HsDGV3_66 NM_024848 1,02 
HsDGV3_76 NM_145015 0,99 
HsDGV3_49 NM_002487 1,14 
HsDGV3_59 NM_015277 1,06 
HsDGV3_88 NM_033116 0,90 
HsNMV1_206 NM_014057 1,07 
HsNMV1_101 NM_006196 1,16 
HsDGV3_83 NM_002595 1,18 
HsDGV3_55 NM_006202 1,15 
HsDGV3_65 NM_021255 1,03 
HsDGV3_50 NM_016831 1,00 
HsDGV3_10 NM_014819 0,87 
HsNMV1_98 NM_000216 1,02 
HsDGV3_79 NM_002841 0,96 
HsDGV3_79 NM_002847 
NM_130842 
NM_130843 
0,96 
HsDGV3_36 NM_006908 
NM_018890 
NM_198829 
1,05 
HsNMV1_103 NM_000983 1,00 
HsNMV1_147 NM_020974 1,19 
HsNMV1_119 NM_006642 0,95 
HsNMV1_111 NM_003919 1,26 
HsNMV1_120 NM_007001 0,97 
HsDGV3_88 NM_032840 0,78 
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HsNMV1_220 NM_052851 0,90 
HsNMV1_129 NM_006588 0,94 
HsNMV1_168 NM_080737 0,95 
HsNMV1_124 NM_007375 1,05 
HsNMV1_136 NM_018201 1,02 
HsDGV3_85 NM_000459 1,05 
HsNMV1_135 NM_018975 0,92 
HsDGV3_85 NM_001024847 
NM_003242 
1,03 
HsDGV3_21 NM_032027 1,05 
HsNMV1_137 NM_017775 0,76 
HsNMV1_116 NM_006048 0,73 
HsDGV3_16 NM_022832 0,88 
HsDGV3_36 NM_014232 0,90 
HsNMV1_112 NM_004781 1,10 
HsDGV3_31 NM_052867 0,93 
HsNMV1_216 NM_015378 1,05 
HsNMV1_121 NM_007187 1,06 
HsDGV3_85 NM_003390 1,00 
HsNMV1_147 NM_020899 1,16 
HsDGV3_28 NM_015336 0,78 
HsNMV1_158 NM_030634 1,28 
HsNMV1_162 NM_032497 0,97 
HsNMV1_162 NM_032342 0,65 
HsNMV1_137 NM_017787 1,13 
HsNMV1_187 NM_153367 0,98 
HsNMV1_156 NM_025057 1,13 
HsNMV1_119 NM_018691 0,92 
HsNMV1_153 NM_024573 1,38 
HsNMV1_122 NM_014929 1,10 
 
*Column A: Specific Oligo IDs in the library. Column B: Respective gene accession numbers.  
Column  C: Fold changes in cell viability measured by CTG assay (normalized to negative 
control si-GFP). 
Supplementary 
 101 
Table 7 (A)- Top 20 pathways which are affected by CHMP5 over-expression 48h after 
transfection.  
 
Down-Regulated pathways by  
CHMP5 over-expression after 48h 
 
Up- Regulated pathways by 
CHMP5 over-expression after 48h 
 
A B C D E F 
Pathway Name Histogram 
 
Score Pathway Name 
 
Histogram Score 
Endometrial cancer 
 
359  
Ribosome 
 
 
326 
Acute myeloid 
leukemia  
352 Caprolactam 
degradation  
294 
Thyroid cancer 
 
347 Biosynthesis of 
steroids  
291 
Huntington's 
disease  
313 Benzoate 
degradation via 
CoA ligation  
286 
Polyunsaturated 
fatty acid 
biosynthesis  
307 
Aminosugars 
metabolism 
 
273 
Sphingolipid 
metabolism  
293 Oxidative 
phosphorylation  
225 
Methionine 
metabolism  
272 Keratan sulfate 
biosynthesis  
215 
Insulin signaling 
pathway  
264 Limonene and 
pinene degradation  
211 
Carbon fixation 
 
208 
Proteasome 
 
172 
Glycosaminoglycan 
degradation 
 
208 Glycosylphosphatid
ylinositol(GPI)-
anchor biosynthesis  
162 
Selenoamino acid 
metabolism  
208 Propanoate 
metabolism  
152 
Amyotrophic lateral 
sclerosis (ALS)  
206 
DNA polymerase 
 
146 
Glycan structures - 
degradation  
192 Riboflavin 
metabolism  
141 
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Notch signaling 
pathway  
175 Butanoate 
metabolism  
141 
Pathogenic 
Escherichia coli 
infection - EHEC 
 
168 SNARE interactions 
in vesicular 
transport  
135 
Adipocytokine 
signaling pathway  
165 TGF-beta signaling 
pathway  
134 
Prostate cancer 
 
165 gamma-
Hexachlorocyclohe
xane degradation  
134 
Pathogenic 
Escherichia coli 
infection - EPEC 
 
161 Porphyrin and 
chlorophyll 
metabolism  
116 
Aminoacyl-tRNA 
biosynthesis  
148 Fatty acid 
metabolism  
102 
Pentose phosphate 
pathway  
129 p53 signaling  
pathway 
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*Column A and D: name of the pathways, column B and E histogram of the genes which are 
down or up regulated in proper pathways, column C and F: Scores which are obtained by 
CGPA-software for each pathway. 
Table 7 (B)- Top 20 pathways which are affected by CHMP5 silencing 48h after 
transfection.  
Dowun- Regulated pathways  
by CHMP5 knock-down after 48h 
 
Up- Regulated pathways by  
CHMP5 knock-down after 48h 
 
A B C F G H 
Pathway Name Histogram 
 
Score Pathway Name 
 
Histogram Score 
Valine, leucine 
and isoleucine 
degradation 
 
 
359 
Cell cycle 
 
 
326 
Propanoate 
metabolism  
352 p53 signaling 
pathway  
294 
Oxidative 
phosphorylation 
 
347 Urea cycle and 
metabolism of amino 
groups  
291 
Citrate cycle (TCA 
cycle)  
313 
Bladder cancer 
 
286 
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Fatty acid 
metabolism  
307 MAPK signaling 
pathway  
273 
Ubiquinone 
biosynthesis  
293 Chronic myeloid 
leukemia  
225 
Glycosylphosphati
dylinositol(GPI)-
anchor 
biosynthesis 
 
272 
Thyroid cancer 
 
215 
Proteasome 
 
 
264 Notch signaling 
pathway 
 
 
211 
Caprolactam 
degradation  
208 Acute myeloid 
leukemia 
 
172 
Aminoacyl-tRNA 
biosynthesis  
208 
Prostate cancer 
 
162 
Pentose phosphate 
pathway  
208 
Endometrial cancer 
 
152 
Limonene and 
pinene degradation 
 
 
206 Non-small cell 
lung cancer 
 
 
146 
Benzoate 
degradation via 
CoA ligation 
 
192 
mTOR signaling 
pathway 
 
141 
beta-Alanine 
metabolism 
 
175 Pathogenic 
Escherichia coli 
infection - EPEC  
141 
Pyruvate 
metabolism  
168 Small cell lung 
cancer  
135 
Biosynthesis of 
steroids  
165 Pathogenic 
Escherichia coli 
infection - EHEC  
134 
Polyunsaturated 
fatty acid 
biosynthesis  
165 
Colorectal cancer 
 
134 
Butanoate 
metabolism  
161 
Cholera - Infection 
 
116 
Glutamate 
metabolism  
148 
Parkinson's disease 
 
102 
Arginine and 
proline metabolism  
129 
Renal cell carcinoma 
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*Column A and D: name of the pathways, column B and E histogram of the genes which are 
down or up regulated in proper pathways, column C and F: Scores which are obtained by 
CGPA-software for each pathway. 
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Table 8- Down-regulated and up-regulated genes upon CHMP5 over-expression at 
different time points.  
 
*Common genes of top 100 in comparison of time points 48h and 72h (A, B) 
 
 
 
Figure 30- Murine cDNA-CHMP5 (nucleotide 609-631) and Human sh-CHMP5 
(nucleotide 631-653) sequences. The mismatches are shown in bold. 
 
Supplementary 
 105 
 
 
 
Figure 31- Expression of CHMP5, Birc4 and FLIP in transfected HEK293T cells. The 
level of CHMP5, Birc4 and FLIP mRNA was measured by qRT-PCR 48h after transfection 
and values were normalized to GAPDH mRNA levels, which was used as loading control. Si-
GFP transfected cells used as negative control.  
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